2019-11-12T16:38:20-06:00 2018-12-31 521392008 GELMAN ROSENBERG & FREEDMAN 4550 MONTGOMERY AVE SUITE 800N BETHESDA MD 208142930 990 2018-01-01 911157127 PATH PATH 2062853500 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 BRIAN NEVILLE CHIEF OF ACCOUNTING 2062853500 2019-11-12 1 RICHARD J LOCASTRO CPA P00288314 3019519090 75.103.231.202 2019-11-12 17:38:15 ES P 981DD7ACBC606C3C3562579832A13CC83ACA1B41 60F5620986AF14763908AFE7AC6F4ECEC523E148 2018 2020-04-17 16:48:07Z BRIAN NEVILLE 2201 WESTLAKE AVENUE NO 200 SEATTLE WA 98121 388448491 0 X WWW.PATH.ORG X 1981 WA SEE PART III, LINE 1. 14 14 787 0 0 547406 347844394 305315221 41949 1500 2168657 3037130 5225302 980560 355280302 309334411 66754537 62762146 0 0 136040867 139545675 0 0 3186635 126837131 110458648 329632535 312766469 25647767 -3432058 467947698 237501233 50797492 202931874 417150206 34569359 X PATH'S MISSION IS TO ADVANCE HEALTH EQUITY THROUGH INNOVATION AND PARTNERSHIPS. (CONTINUED ON SCHEDULE O) 0 0 128263294 15311912 1500 GLOBAL HEALTH PROGRAMS: PATH'S GLOBAL HEALTH PROGRAMS DIVISION BRINGS TOGETHER OUR SIGNIFICANT COUNTRY EXPERIENCE AND DEEP TECHNICAL EXPERTISE TO FACILITATE THE ORGANIZATION'S ABILITY TO ACHIEVE IMPACT THROUGH INNOVATIVE APPROACHES AND SOLUTIONS. THIS DIVISION MANAGES PATH'S PRESENCE IN COUNTRY OFFICES AND IS RESPONSIBLE FOR PATH'S SCIENTIFIC EXPERTISE IN MALARIA AND NEGLECTED TROPICAL DISEASES; HIV AND TUBERCULOSIS; MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; NONCOMMUNICABLE DISEASES; HEALTH SYSTEMS INNOVATION AND DELIVERY; AND DIGITAL HEALTH SOLUTIONS.(CONTINUED ON SCHEDULE O)MALARIA AND NEGLECTED TROPICAL DISEASESPATH PARTNERS WITH GOVERNMENTS, THE PRIVATE SECTOR, AND FUNDERS ACROSS THE GLOBE TO BRING THE WORLD CLOSER TO MALARIA ERADICATION. MORE THAN 200 PATH STAFF MEMBERS WORK ON MALARIA IN MORE THAN 30 COUNTRIES. OUR STRATEGY INCLUDES OPTIMIZING THE DELIVERY OF CURRENT TOOLS AND APPROACHES TO ENSURE THEY REACH THE PEOPLE WHO NEED THEM, DEVELOPING NEW STRATEGIES FOR ELIMINATION, DEVELOPING NEXT-GENERATION TOOLS TO OVERCOME EMERGING CHALLENGES, AND CREATING INNOVATIVE PARTNERSHIPS AND FUNDING MODELS TO ENSURE THAT OUR PROGRAMS ARE SUSTAINABLE AND EFFECTIVE. APPROACHES PIONEERED BY PATH HAVE CONTRIBUTED TO REMARKABLE PROGRESS TOWARD CONTROLLING AND ELIMINATING MALARIA, WITH NEARLY 7 MILLION LIVES SAVED SINCE 2000.IN 2018, OUR MALARIA CONTROL AND ELIMINATION PARTNERSHIP IN AFRICA (MACEPA) PROGRAM CONTINUED TO SUPPORT THE GOVERNMENTS OF ETHIOPIA, SENEGAL, AND ZAMBIA AS THEY STRIVE TO ACHIEVE THEIR MALARIA ELIMINATION GOALS. WE HELPED BY SCALING UP PREVENTION AND TREATMENT, EVALUATING SENSITIVE DIAGNOSTIC TOOLS, ESTABLISHING RAPID REPORTING SYSTEMS, AND SUPPORTING POPULATION-WIDE, DRUG-BASED STRATEGIES, SUCH AS MASS DRUG ADMINISTRATION. THROUGH OUR PROGRAM FOR THE ADVANCEMENT OF MALARIA OUTCOMES, PATH ASSISTED THE GOVERNMENT OF ZAMBIA IN REACHING ITS GOALS FOR ELIMINATING LOCAL MALARIA INFECTION AND DISEASE. THIS WORK FOCUSED ON BEDNETS, MALARIA IN PREGNANCY, SOCIAL BEHAVIOR CHANGE, CASE MANAGEMENT, SURVEILLANCE, AND MONITORING & EVALUATION. THE PROGRAM'S GEOGRAPHIC FOCUS IS ON PROVINCES WITH THE HIGHEST MALARIA PREVALENCE AMONG CHILDREN.PATH ALSO WORKED TO IMPROVE DATA FOR MALARIA CONTROL DECISION-MAKING AND SURVEILLANCE. IN ZAMBIA, FOR EXAMPLE, THE VISUALIZE NO MALARIA PROJECT-A GROUNDBREAKING PARTNERSHIP WITH A SEATTLE-BASED SOFTWARE COMPANY AND A COALITION OF OTHER TECHNOLOGY COMPANIES-CONTINUED TO EXPAND. THIS PROJECT EQUIPS HEALTH WORKERS AND OFFICIALS WITH REAL-TIME DATA VISUALIZATION TOOLS TO SEE WHERE MALARIA IS APPEARING SO THEY CAN DEPLOY RESOURCES TO HALT ITS SPREAD. IN WESTERN KENYA, PATH ASSESSED THE POTENTIAL CONTRIBUTION OF MALARIA TESTING DATA FROM PREGNANT WOMEN ATTENDING ANTENATAL CLINICS AS A MEANS TO BOLSTER SURVEILLANCE.IN 2018, PATH ALSO WORKED WITH THE WORLD HEALTH ORGANIZATION (WHO) AND OTHER PARTNERS TO PREPARE FOR PILOT IMPLEMENTATION OF THE RTS,S MALARIA VACCINE IN SELECTED AREAS OF GHANA, KENYA, AND MALAWI. VACCINATIONS ARE DUE TO BEGIN IN 2019. PATH CONTINUED TO DEVELOP AND EVALUATE NEW VECTOR-CONTROL TOOLS SUCH AS NEXT-GENERATION INDOOR RESIDUAL SPRAYING (IN PARTNERSHIP WITH THE INNOVATIVE VECTOR CONTROL CONSORTIUM, THE US PRESIDENT'S MALARIA INITIATIVE, ABT ASSOCIATES, AND THE GLOBAL FUND). THIS WORK IS GENERATING EVIDENCE TO SUPPORT TIMELY DECISION-MAKING AROUND THE ADOPTION OF NEW INSECTICIDES THAT ARE EFFECTIVE AGAINST PYRETHROID-RESISTANT MOSQUITOES. PATH ALSO LED EVALUATION AND DATA-FOR-DECISION-MAKING ACTIVITIES UNDER VECTORLINK, THE US AGENCY FOR INTERNATIONAL DEVELOPMENT'S (USAID'S) FLAGSHIP VECTOR-CONTROL PARTNERSHIP. IN ADDITION, WE DIRECTED EVIDENCE-GENERATION ACTIVITIES UNDER THE NEW NETS PROJECT, FUNDED BY UNITAID AND THE GLOBAL FUND, TO HELP SCALE UP ACCESS TO AND USE OF NEW LONG-LASTING INSECTICIDE-TREATED NETS.TO ADDRESS THE TWIN THREATS OF INSECTICIDE RESISTANCE AND OUTDOOR BITING BY MOSQUITOES, PATH CONTINUED THE DEVELOPMENT AND EVALUATION OF ATTRACTIVE TARGETED SUGAR BAITS, WHICH PRESENT A SUGAR MEAL FOR MOSQUITOES THAT IS LACED WITH AN INSECTICIDE. PATH ALSO SUPPORTED THE DEVELOPMENT OF A NEW, HIGHLY SENSITIVE RAPID DIAGNOSTIC TEST THAT OFFERS A GREATER THAN TENFOLD IMPROVEMENT IN DETECTION OF THE MOST COMMON MALARIA PARASITE. FINALLY, WE ADVANCED WORK ON A POINT-OF-CARE DIAGNOSTIC TEST FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE DEFICIENCY, A CONDITION THAT CAN COMPLICATE MALARIA TREATMENT.IN PATH'S EFFORTS TO FIGHT NEGLECTED TROPICAL DISEASES, OUR WORK INCLUDES DEFINING PRODUCT NEEDS; DEVELOPING TARGET PRODUCT PROFILES; ENGAGING WITH STAKEHOLDERS; CONDUCTING LABORATORY AND FIELD TESTS AND EVALUATIONS; TRANSFERRING TECHNOLOGY AND SECURING MANUFACTURING, DEVELOPMENT, AND COMMERCIALIZATION AGREEMENTS; COMMERCIALIZING PRODUCTS AND COLLATERAL; AND SUPPORTING PRODUCT LAUNCH. MUCH OF THIS WORK IS ACCOMPLISHED VIA PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION DIVISION.HIV AND TUBERCULOSISPATH CONTINUED TO CONTRIBUTE TO HIV PREVENTION AND EPIDEMIC CONTROL IN 2018 BY FOCUSING PROGRAMMING ON THE KEY AND HIGH-PRIORITY POPULATIONS OF ADOLESCENT GIRLS AND YOUNG WOMEN, PEOPLE WITH BOTH HIV AND TUBERCULOSIS (TB), SEX WORKERS AND THEIR CLIENTS, MEN WHO HAVE SEX WITH MEN, PEOPLE WHO INJECT DRUGS, AND TRANSGENDER INDIVIDUALS. WE ADVANCED PROGRAMMING ACROSS MULTIPLE TECHNOLOGY AND SERVICE DELIVERY PLATFORMS-FROM DEVICES, TOOLS, AND DIAGNOSTICS TO SERVICE DELIVERY INNOVATIONS AND ADVOCACY. PATH'S WORK IN DIAGNOSTICS FOCUSED ON FILLING GAPS IN FOUR CRITICAL AREAS: SELF-TESTING, EARLY INFANT DIAGNOSIS, TB DETECTION AMONG PEOPLE LIVING WITH HIV, AND VIRAL LOAD DETECTION. WE FOCUSED ON UNDERSTANDING THE BARRIERS THAT RESTRICT ACCESS TO HIGH-QUALITY DIAGNOSTICS AND ADVANCING NEW PRODUCTS TO OVERCOME THESE OBSTACLES. TO INFORM DESIGN AND DELIVERY OF NEXT-GENERATION HIV SELF-TESTS, PATH EMPLOYED USER-CENTERED DESIGN METHODOLOGIES TO CREATE USER PERSONAS REPRESENTING KEY POPULATIONS. PATH ALSO WORKED TO EVALUATE AND ADVANCE DEVICES TO PROVIDE LONG-TERM ANTIRETROVIRAL DELIVERY FOR PRE-EXPOSURE PROPHYLAXIS (PREP) AND HIV TREATMENT. THESE DEVICES INCLUDE MICROARRAY PATCHES FOR TRANSDERMAL DELIVERY AND AN APPLICATOR TO SUBCUTANEOUSLY INSERT BIODEGRADABLE IMPLANTS. WE ALSO WORKED ON A PEDIATRIC-FRIENDLY DOSAGE FORM OF ANTIRETROVIRAL DRUGS, USING OUR FAST-DISSOLVING TABLET TECHNOLOGY.THROUGH THE AIDS, POPULATION, AND HEALTH INTEGRATED ASSISTANCE PROGRAM PLUS (APHIAPLUS PROJECT), PATH HELPED TO INTEGRATE HEALTH SERVICES IN WESTERN KENYA AND ENABLE MORE PEOPLE TO ACCESS A GREATER SPECTRUM OF SERVICES. SINCE 2011, THE PATH-LED TEAM HAS BUILT THE CAPACITY OF HEALTH CARE WORKERS AND FACILITIES TO DELIVER HIGH-QUALITY SERVICES FOR HIV, TB, SEXUAL AND REPRODUCTIVE HEALTH, AND ADOLESCENT HEALTH; STRENGTHENED LINKAGES BETWEEN HEALTH FACILITIES AND COMMUNITIES TO EXPEDITE ACCESS TO HIV CARE AND TREATMENT; ESTABLISHED COMMUNITY SUPPORT SYSTEMS FOR PEOPLE LIVING WITH HIV AND THEIR FAMILIES; AND EMPOWERED AND MOBILIZED COMMUNITIES AROUND HIV PREVENTION AND OUTREACH.IN 2018, PATH TRANSITIONED HIV ACTIVITIES IN KENYA'S FORMER NYANZA PROVINCE TO USAID'S PATH-LED AFYA ZIWANI PROJECT, WHILE CONTINUING HIV AND TB SERVICE DELIVERY IN THE FORMER WESTERN PROVINCE THROUGH APHIAPLUS. WITH FUNDING FROM THE US PRESIDENT'S EMERGENCY PLAN FOR AIDS RELIEF DREAMS INITIATIVE, APHIAPLUS AND THE AFYA ZIWANI PROJECT INTENSIFIED EFFORTS TO REACH MORE THAN 77,500 ADOLESCENT GIRLS AND YOUNG WOMEN IN KENYA WITH INTERVENTIONS TO REDUCE THEIR VULNERABILITY TO HIV AND IMPROVE THEIR ACCESS TO SERVICES. THIS WORK INCLUDED THE CREATION OF MORE THAN 200 SAFE SPACES AND IMPROVED ACCESS TO YOUTH-FRIENDLY FAMILY PLANNING, HIV, AND GENDER-BASED VIOLENCE SERVICES. IN THE DEMOCRATIC REPUBLIC OF THE CONGO (DRC), PATH CONTINUED TO LEAD USAID-FUNDED EFFORTS TO IMPROVE HIV/AIDS SERVICES. IN 2018, THIS WORK FOCUSED ON TWO HIGH-PREVALENCE PROVINCES UNDER THE INTEGRATED HIV/AIDS PROJECT IN HAUT-KATANGA AND LUALABA. PATH PROVIDED TECHNICAL ASSISTANCE TO 162 HEALTH FACILITIES, 18 HEALTH ZONES, AND 5 NONGOVERNMENTAL ORGANIZATIONS TO INCREASE TARGETED TESTING EFFORTS, ENROLL ALL IDENTIFIED HIV-POSITIVE INDIVIDUALS ON TREATMENT, SCALE UP VIRAL LOAD TESTING, AND ROLL OUT DIFFERENTIATED CARE MODELS TO IMPROVE RETENTION IN TREATMENT. AT THE END OF DECEMBER 2018, PATH WAS SUPPORTING MORE THAN 33,000 INDIVIDUALS IN THE DRC ON ANTIRETROVIRAL THERAPY. 88257285 37275906 ESSENTIAL MEDICINES: PATH'S ESSENTIAL MEDICINES DIVISION DEVELOPS AND DELIVERS LIFESAVING VACCINES AND DRUGS FOR WOMEN, CHILDREN, AND COMMUNITIES AROUND THE GLOBE.(CONTINUED ON SCHEDULE O)CENTER FOR VACCINE INNOVATION AND ACCESSPATH'S CENTER FOR VACCINE INNOVATION AND ACCESS (CVIA) ALIGNS EXPERTISE ACROSS EVERY STAGE OF VACCINE RESEARCH, DEVELOPMENT, AND INTRODUCTION TO MAKE VACCINES GLOBALLY AVAILABLE TO MORE COMMUNITIES, PARTICULARLY IN LOW- AND MIDDLE-INCOME COUNTRIES. OUR PORTFOLIO INCLUDES MORE THAN TWO DOZEN VACCINE PRODUCTS IN DEVELOPMENT OR ALREADY IN USE, WITH AN EMPHASIS ON THE LEADING INFECTIOUS CAUSES OF CHILD DEATHS AND DISEASES WORLDWIDE.FOR EXAMPLE, IN 2018 WE CONTINUED TO PARTNER WITH COUNTRIES TO EXPAND COVERAGE OF JAPANESE ENCEPHALITIS (JE) VACCINE, WHICH PATH HELPED SHEPHERD THROUGH THE GLOBAL REGULATORY PROCESS AND SCALE UP. WITH SUPPORT FROM PATH, THE GOVERNMENT OF INDONESIA LAUNCHED JE VACCINATION CAMPAIGNS IN THE PROVINCE OF BALI. PATH ALSO PROVIDED TECHNICAL ASSISTANCE IN THE LEAD-UP TO JE VACCINATION CAMPAIGNS IN SELECT, HIGH-RISK REGIONS IN THE PHILIPPINES.IN 2018, WE CONTINUED A PHASE 2 STUDY OF A POLYVALENT MENINGOCOCCAL MENINGITIS VACCINE IN YOUNG CHILDREN IN MALI. THE VACCINE, DEVELOPED BY SERUM INSTITUTE OF INDIA PVT. LTD., BUILDS ON THE SUCCESS OF MENAFRIVAC, A VACCINE AGAINST MENINGOCOCCAL MENINGITIS SEROGROUP A THAT WAS LICENSED AND INTRODUCED IN 2010. THE POLYVALENT VACCINE TARGETS SEROGROUPS A, C, W, X, AND Y. THE VACCINE IS DESIGNED FOR USE IN THE AFRICAN "MENINGITIS BELT" REGION AND WILL BE THE FIRST VACCINE TO TARGET SEROGROUP X. TO PREVENT MALARIA, PATH IS ACCELERATING THE DEVELOPMENT OF A WIDE VARIETY OF MALARIA VACCINE CANDIDATES AND APPROACHES. IN 2018, PATH CONTINUED TO WORK WITH WHO AND OTHER PARTNERS TO PREPARE FOR PILOT IMPLEMENTATION OF THE RTS,S VACCINE IN SELECTED AREAS OF GHANA, KENYA, AND MALAWI. WITH PARTNERS, PATH CONTINUED TO ADVANCE RESEARCH INTO WHETHER REDUCING THE DOSE LEVEL OF RTS,S AND DELAYING THE ADMINISTRATION OF DOSES HAS THE POTENTIAL TO FURTHER AID MALARIA ELIMINATION EFFORTS BY STRETCHING LIMITED VACCINE SUPPLIES AND PROTECTING AS MANY PEOPLE AS POSSIBLE. FIELD TESTING OF THE DELAYED FRACTIONAL DOSE REGIMEN BEGAN AT A RESEARCH CENTER IN KENYA IN 2018.PATH'S DEFEAT DIARRHEAL DISEASE INITIATIVE, HOUSED WITHIN CVIA, CONTINUED ITS ONGOING WORK TO GENERATE INVESTMENTS IN ROTAVIRUS, ENTEROTOXIGENIC ESCHERICHIA COLI, AND SHIGELLA VACCINES WITHIN THE CONTEXT OF AN INTEGRATED PREVENTION AND TREATMENT APPROACH. THE PROJECT RECEIVED STANDALONE FUNDING IN LATE 2018 TO CONTINUE EDUCATING OUR TARGET AUDIENCES ON THE LIFELONG CONSEQUENCES OF REPEATED INFECTIONS. IN 2018, PATH ALSO HELPED INTRODUCE AND ADVANCE ACCESS TO CURRENTLY AVAILABLE ENTERIC VACCINES, INCLUDING THE NEWLY WHO-PREQUALIFIED ROTAVAC AND ROTASIIL ROTAVIRUS VACCINES AND TYPBAR-TCV TYPHOID CONJUGATE VACCINE. PATH LED AND/OR SUPPORTED ONGOING PHASE 4 CLINICAL TRIALS, CONDUCTED VACCINE IMPACT AND COST-EFFECTIVENESS ANALYSES, AND DISSEMINATED EVIDENCE THROUGH ADVOCACY AND COMMUNICATIONS TO INFORM COUNTRY DECISION-MAKING AROUND VACCINE INTRODUCTION AND PRODUCT SWITCHES.IN 2018, PATH CONTINUED TO SUPPORT SOUTH AFRICAN VACCINE MANUFACTURER THE BIOVAC INSTITUTE IN PRECLINICAL DEVELOPMENT OF A VACCINE AGAINST GROUP B STREPTOCOCCUS, THE LEADING CAUSE OF BACTERIAL SEPSIS AND MENINGITIS IN YOUNG INFANTS WORLDWIDE. THE INTENDED VACCINE POPULATION IS PREGNANT WOMEN-PART OF A STRATEGY THAT BOOSTS IMMUNITY AGAINST THE BACTERIUM AND TRANSFERS PROTECTIVE ANTIBODIES TO THE DEVELOPING BABY. ALSO IN 2018, PATH CONTINUED A PROJECT TO COORDINATE A CONSORTIUM OF NINE INDEPENDENT RESEARCH INSTITUTIONS TO COLLATE AND SYNTHESIZE EXISTING EVIDENCE AND EVALUATE NEW DATA ON THE POTENTIAL FOR SINGLE-DOSE HPV VACCINATION. ALTHOUGH MANY COUNTRIES HAVE INTRODUCED HPV VACCINES INTO THEIR NATIONAL IMMUNIZATION SCHEDULES, SOME LOW- AND LOWER-MIDDLE-INCOME COUNTRIES HAVE DELAYED INTRODUCTION BECAUSE OF FINANCIAL, LOGISTICAL, OR OTHER BARRIERS. FOR THESE COUNTRIES, A SINGLE-DOSE REGIMEN COULD ACCELERATE INTRODUCTION OF HPV VACCINES INTO NATIONAL IMMUNIZATION SCHEDULES.DRUG DEVELOPMENTTHROUGH OUR WORK ON DRUG DEVELOPMENT AND INTRODUCTION, PATH HELPS TO ENSURE THAT PEOPLE AROUND THE WORLD, ESPECIALLY CHILDREN LIVING IN LOW-RESOURCE SETTINGS, HAVE RELIABLE ACCESS TO LIFESAVING MEDICINES. WE WORK TO ADVANCE THE MOST PROMISING SOLUTIONS FOR A RANGE OF URGENT GLOBAL HEALTH CHALLENGES, INCLUDING ENTERIC AND DIARRHEAL DISEASES, NEGLECTED TROPICAL DISEASES, HIV/AIDS, AND MALARIA. DRAWING ON AN ENDURING COMMITMENT TO HEALTH EQUITY AND A UNIQUE PARTNERSHIP APPROACH THAT SPANS THE ACADEMIC, PRIVATE, NONPROFIT, AND GOVERNMENT SECTORS, OUR WORK OVERTURNS BARRIERS TO HEALTH AT EVERY STAGE OF DRUG DEVELOPMENT AND USE-FROM EARLY RESEARCH TO POLICY INTRODUCTION.IN 2018, IN COLLABORATION WITH PARTNERS, PATH CONTINUED TO ADVANCE A PORTFOLIO OF DRUG PROJECTS TO REDUCE THE GLOBAL BURDEN OF ENTERIC AND DIARRHEAL DISEASE AMONG YOUNG CHILDREN. FOR EXAMPLE, WE MADE SIGNIFICANT PROGRESS IN VALIDATING A NEW RESEARCH ASSESSMENT TOOL FOR ENVIRONMENTAL ENTERIC DYSFUNCTION (EED)-AN INTESTINAL DISORDER COMMON AMONG CHILDREN LIVING IN LOW-RESOURCE SETTINGS THAT IS ASSOCIATED WITH INCREASED RISK OF STUNTING, COGNITIVE DEFICITS, AND REDUCED RESPONSIVENESS TO ORAL VACCINES. THE TOOL IS DESIGNED TO MEASURE MULTIPLE BIOMARKERS, INCLUDING THOSE OF EED, SYSTEMIC INFLAMMATION, GROWTH HORMONE RESISTANCE, AND MICRONUTRIENTS, AND COULD BE AN ASSET FOR EED CLINICAL RESEARCH IN LOW-INCOME COUNTRIES. THE DIARRHEA INNOVATIONS GROUP (DIG), AN INTERNATIONAL NETWORK OF CHILD HEALTH STAKEHOLDERS HOUSED WITHIN AND CO-CHAIRED BY PATH, CONTINUED ITS WORK TO IMPROVE COLLABORATION FOR DIARRHEAL DISEASE RESEARCH AND ACCELERATE PROGRESS THROUGH PARTNERSHIPS. IN NOVEMBER 2018, DIG MEMBERS PETITIONED WHO TO INCLUDE CO-PACKAGED ORAL REHYDRATION SOLUTION (ORS) AND ZINC IN ITS MODEL LIST OF ESSENTIAL MEDICINES. JOINT ADMINISTRATION OF ORS AND ZINC HAS LONG BEEN RECOMMENDED FOR MANAGEMENT OF PEDIATRIC DIARRHEA, YET NO FORMAL GUIDANCE ON CO-PACKAGED ORS-ZINC EXISTED, AND THE NUMBER OF CHILDREN WITH DIARRHEA RECEIVING THE OPTIMAL TREATMENT REMAINS UNACCEPTABLY LOW AT LESS THAN 7 PERCENT. ONCE ADOPTED BY WHO, THIS GLOBAL POLICY CHANGE WILL HELP PRIORITIZE BOTH ORS AND ZINC AS THE DIARRHEA MANAGEMENT STANDARD AT THE NATIONAL LEVEL, ULTIMATELY IMPROVING COVERAGE AND SAVING LIVES.ALSO IN 2018, WE CONTINUED OUR WORK TO DEVELOP NEW THERAPEUTICS FOR CRYPTOSPORIDIUM, ONE OF THE KEY PATHOGENS RESPONSIBLE FOR DIARRHEAL MORBIDITY IN CHILDREN UNDER FIVE YEARS OF AGE. IN ADDITION, WE PREPARED FOR A STUDY TO TEST THE INVESTIGATIONAL NEW DRUG IOWH032 AS AN ANTISECRETORY THERAPY FOR THE TREATMENT OF CHOLERA.PARALLEL TO DRUG RESEARCH AND DEVELOPMENT, PATH CONTINUED OUR WORK TO ENSURE THAT ESSENTIAL MEDICINES ARE RELIABLY ACCESSIBLE TO THE PEOPLE WHO NEED THEM. OUR ACCESS TO ESSENTIAL MEDICINES INITIATIVE CARRIED OUT AN IN-DEPTH ANALYSIS OF THE WHO ESSENTIAL MEDICINES LISTS AND DEVELOPED A TOOL TO HELP IDENTIFY AND PRIORITIZE MEDICINES WITH SUBOPTIMAL ACCESS AND USE. THE TOOL IS DESIGNED TO HELP GLOBAL AND COUNTRY STAKEHOLDERS BETTER UNDERSTAND ACCESS GAPS AND THE HEALTH IMPACT POTENTIAL OF ESSENTIAL MEDICINES. THIS, IN TURN, CAN GUIDE DECISION-MAKING ON ACTIVITIES AND INVESTMENTS. IN 2018, WE INTRODUCED THE TOOL TO A NUMBER OF PARTNERS AND FUNDERS AND EXPLORED OPPORTUNITIES TO MAKE IT PUBLICLY AVAILABLE. 26496089 4929933 TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION: PATH'S TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION DIVISION BEGAN THE YEAR AS TECHNOLOGY DEVELOPMENT AND INTRODUCTION (TDI). AS SUCH, IT WAS AN INTEGRATED GLOBAL PLATFORM FOR END-TO-END ADVANCEMENT OF HIGH-IMPACT DEVICES, TOOLS, DIAGNOSTICS, AND IN-COUNTRY "IMPACT LABS" THAT ADDRESS GLOBAL, REGIONAL, AND COUNTRY HEALTH NEEDS. IN JULY 2018, TDI GREW TO INCLUDE ADDITIONAL PROGRAMS-SUCH AS MARKET DYNAMICS, DIGITAL & DATA, AND MONITORING & EVALUATION-AND WAS RENAMED TECHNOLOGY, ANALYTICS, AND MARKET INNOVATION (TAMI).(CONTINUED ON SCHEDULE O)DEVICES AND TOOLSTHE DEVICES AND TOOLS PROGRAM WITHIN TAMI IS PATH'S INNOVATIVE PRODUCT DEVELOPMENT ARM. THE PROGRAM WORKS WITH PUBLIC- AND PRIVATE-SECTOR PARTNERS AROUND THE WORLD TO DEVELOP, TEST, REFINE, INTRODUCE, AND SCALE AFFORDABLE TECHNOLOGIES TO IMPROVE THE HEALTH OF PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES.IN 2018, THE PROGRAM'S MILESTONES INCLUDED TRANSFERRING THE DESIGN OF THE BUBBLE CONTINUOUS POSITIVE AIRWAY PRESSURE DEVICE AND OXYGEN BLENDER TO A MANUFACTURER, BEGINNING FIELD EVALUATIONS FOR A FREEZE-SAFE VACCINE CARRIER IN NEPAL WITH A STUDY PARTNER, AND COMPLETING A PROGRAMMATIC AND HUMAN FACTORS EVALUATION OF THREE BLOW-FILL-SEAL VACCINE CONTAINERS IN AFRICA AND ASIA, AS WELL AS RECLASSIFICATION OF THE FEMALE CONDOM BY THE US FOOD & DRUG ADMINISTRATION FROM A CATEGORY III TO CATEGORY II MEDICAL DEVICE.STAFF PRODUCED 17 JOURNAL ARTICLES AND REPORTS ON RESEARCH FINDINGS, RANGING FROM ASSESSMENTS OF TECHNOLOGIES TO IMPROVE IMMUNIZATION TO EVALUATIONS OF NEONATAL RESUSCITATORS.DIAGNOSTICSPATH'S WORK TO ADVANCE ACCURATE DIAGNOSTIC TECHNOLOGIES THAT STRENGTHEN HEALTH EQUITY INCLUDES TOOLS TO DETECT AND MONITOR NEGLECTED TROPICAL DISEASES, MALARIA, HIV, POLIO, AND NONCOMMUNICABLE DISEASES.IN 2018, OUR PIONEERING WORK IN MALARIA DIAGNOSTICS INCLUDED DEVELOPING NEW TOOLS TO IMPROVE DETECTION OF THE MALARIA PARASITE AND TESTS TO GUIDE THE CLINICAL CARE OF PATIENTS. WITH OUR RESEARCH AND DEVELOPMENT PARTNERS, PATH ADVANCED SEVERAL POINT-OF-CARE TESTS FOR GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) DEFICIENCY, A CONDITION THAT CAN COMPLICATE TREATMENT OF PLASMODIUM VIVAX MALARIA. THIS INCLUDED COMPLETING FIELD-BASED STUDIES OF A QUANTITATIVE BIOSENSOR AND FACILITATING A COMMUNITY OF PRACTICE FOR GLOBAL RESEARCHERS WORKING TO ADVANCE G6PD DIAGNOSTICS. PATH DEVELOPED GEODX, A COMPUTER PROGRAM THAT ESTIMATES THE PLASMODIUM VIVAX BURDEN PER HEALTH FACILITY, THE TOTAL QUANTITY OF G6PD TESTS THAT WOULD BE REQUIRED PER COUNTRY, AND THE ASSOCIATED COST. ADDITIONALLY, WE COMPLETED VALIDATION OF A MULTIPLEXED ARRAY THAT MEASURES MULTIPLE MALARIA ANTIGENS AT LOW CONCENTRATIONS TO SUPPORT THE DEVELOPMENT OF IMPROVED RAPID DIAGNOSTIC TESTS.WITH PARTNERS, PATH ESTABLISHED A BIOREPOSITORY TO SUPPORT THE DEVELOPMENT OF IMPROVED PREECLAMPSIA DIAGNOSTICS. ADDITIONALLY, PATH CREATED NEW TRAINING MATERIALS, INCLUDING A USER AID, TO SUPPORT OPERATIONS RESEARCH ON AN IMPROVED PREECLAMPSIA TEST.IN COLLABORATION WITH A PRIVATE-SECTOR PARTNER, PATH WORKED TO SIGNIFICANTLY LOWER THE PRICE PER ANALYTE FOR A MULTIPLEXED TOOL THAT DETECTS UP TO SEVEN NUTRITION- AND DISEASE-RELATED BIOMARKERS FOR POPULATION-BASED SURVEILLANCE OF MICRONUTRIENT DEFICIENCIES.FURTHER, PATH AND OUR PARTNERS CONDUCTED FIELD STUDIES AND MARKET RESEARCH TO ASSESS AND VALIDATE THE APPLICATION OF A BOVINE ESTRUS DETECTION TEST IN LOW- AND MIDDLE-INCOME COUNTRIES TO IMPROVE LIVELIHOODS AND NUTRITION. THE PRODUCT WAS LAUNCHED WITH DISTRIBUTION PARTNERS IN KENYA, TANZANIA, AND UGANDA.IMPACT LABSPATH'S IMPACT LABS IN INDIA, KENYA, AND SOUTH AFRICA HELP TO ADVANCE THE MOST PROMISING HEALTH TECHNOLOGIES. THESE COUNTRIES HAVE RICH INNOVATION ECOSYSTEMS WITH UNIVERSITIES, PRIVATE-SECTOR FIRMS, AND A GROWING NUMBER OF ENTREPRENEURS FOCUSED ON INNOVATIVE PRODUCTS AND SERVICES THAT MAKE HEALTH CARE MORE AFFORDABLE, ACCESSIBLE, AND EFFECTIVE. THROUGH OUR NETWORK OF IMPACT LABS, PATH CAN LEVERAGE WORLD-CLASS GLOBAL AND COUNTRY EXPERTISE TO ACCELERATE THE DEVELOPMENT AND INTRODUCTION OF SCALABLE DEVICES, TOOLS, AND DIAGNOSTICS FOR HEALTH. THE KENYA IMPACT LAB WAS IN NASCENT STAGES IN 2018; ACTIVITIES FOR INDIA AND SOUTH AFRICA ARE DESCRIBED BELOW. THE INDIA IMPACT LAB WAS OFFICIALLY LAUNCHED IN JANUARY 2018 IN PARTNERSHIP WITH TATA TRUSTS AND THE INDIAN INSTITUTE OF TECHNOLOGY DELHI AS A PLATFORM TO ENABLE LATE-STAGE MEDICAL TECHNOLOGY (MEDTECH) INNOVATIONS TO ACHIEVE MARKET ENTRY, ADOPTION, AND SCALE-UP. IN JULY 2018, THE IMPACT LAB LAUNCHED A 12-MONTH INTENSIVE PROGRAM: SOCIAL ALPHA QUEST FOR HEALTHCARE INNOVATIONS. THE QUEST FEATURED A SYSTEMATIC, COHORT-BASED ENGAGEMENT MODEL WITH TEN SELECTED MEDTECH PRODUCT START-UPS. THE PROGRAM PROVIDED THE START-UPS WITH CONTEXTUAL SUPPORT, GUIDANCE, AND MENTORSHIP IN PRODUCT DEVELOPMENT, CLINICAL EVIDENCE GENERATION, REGULATIONS, QUALITY MANAGEMENT, MARKET UNDERSTANDING, AND PROCUREMENT CHANNELS. THE IMPACT LAB PARTNERED AND SIGNED MEMORANDUMS OF UNDERSTANDING WITH FIVE TOP INDIAN TECHNOLOGY AND BUSINESS INCUBATORS IN THE LIFE SCIENCE AND HEALTH CARE INDUSTRIES TO CONDUCT JOINT PROGRAMS FOR THE DEVELOPMENT OF THE INNOVATION ECOSYSTEM. THE IMPACT LAB ALSO DELIVERED EIGHT CURATED AND FOCUSED KNOWLEDGE PLATFORMS (FOR EXAMPLE, WORKSHOPS, ROUNDTABLES, AND MENTOR MIXERS). FOR THESE, THE IMPACT LAB ENGAGED EXPERTS FROM NUMEROUS LARGE AND SMALL MEDTECH COMPANIES. IN 2018, 60 TO 100 START-UPS PARTICIPATED IN EACH KNOWLEDGE PLATFORM (PRODUCT DEVELOPMENT, LOCAL AND GLOBAL REGULATIONS, STANDARDS, TESTING AND CALIBRATIONS, CERTIFICATION, VENDOR MANAGEMENT, QUALITY MANAGEMENT, AND MARKET ENTRY ASPECTS)-ALL HIGHLY RELEVANT TO THE GROWTH OF MEDTECH START-UPS AND THE INNOVATION ECOSYSTEM.FOR THE SOUTH AFRICA IMPACT LAB, A PRIMARY FOCUS OF 2018 WAS TO RE-ENGAGE AND RE-AFFIRM PATH'S RELATIONSHIP WITH THE SOUTH AFRICAN MEDICAL RESEARCH COUNCIL (SAMRC) AND COMMITMENT TO OUR JOINT GLOBAL HEALTH INNOVATION ACCELERATOR (GHIA) PARTNERSHIP. FOR EXAMPLE, PATH FACILITATED A WORKSHOP WITH THE SAMRC REGARDING KEY COMMERCIALIZATION AND MARKET DYNAMICS CONCEPTS. WE ALSO PROVIDED TECHNICAL ASSISTANCE TO THE SAMRC AND OTHER PARTNERS ON A SUCCESSFUL GRAND CHALLENGES CANADA APPLICATION FOR A MATERNAL HEALTH MEDICAL DEVICE. THESE AND OTHER ACTIVITIES WERE CONDUCTED UNDER A GRANT FROM THE BILL & MELINDA GATES FOUNDATION TO THE SAMRC. THE GRANT WAS AIMED AT BUILDING GHIA'S CAPACITY TO IMPROVE THE AFFORDABILITY AND AVAILABILITY OF HEALTH CARE SERVICES BY SUPPORTING THE DEVELOPMENT AND COMMERCIALIZATION OF MEDICAL TECHNOLOGIES DESIGNED FOR RESOURCE-LIMITED SETTINGS IN SOUTH AFRICA AND BEYOND.MARKET DYNAMICSPATH'S MARKET DYNAMICS PROGRAM ENCOMPASSES EFFORTS TO CHARACTERIZE MARKETS, ASSESS SHORTCOMINGS, AND DESIGN MARKET-BASED INTERVENTIONS TO IMPROVE HEALTH OUTCOMES. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT AND INTRODUCTION. IT BUILDS UPON OUR EXISTING STRENGTH IN COMMERCIALIZATION, ALIGNS EXPERTISE ACROSS TEAMS, AND EXPANDS OUR CAPACITY TO ADDRESS MARKET-BASED ISSUES. IN 2018, OUR WORK FOCUSED ON ASSESSING MARKETS AND IMPROVING MARKET FUNCTIONING FOR MALARIA DRUGS AND DRUG INTERMEDIATES, MALARIA DIAGNOSTICS, OXYGEN THERAPY DEVICES, AND DEVICES FOR TREATMENT OF PRECANCEROUS CERVICAL LESIONS. THE MARKET DYNAMICS PROGRAM ALSO COLLABORATED WITH THE ADVOCACY AND PUBLIC POLICY TEAM TO STRENGTHEN MARKETS FOR MATERNAL AND NEWBORN HEALTH PRODUCTS THROUGH POLICY ADVOCACY. 25764391 5244395 ADVOCACY AND PUBLIC POLICY:PATH'S ADVOCACY AND PUBLIC POLICY TEAM WORKS IN THE UNITED STATES, GLOBALLY WITH MULTILATERAL AGENCIES ENGAGED IN HEALTH POLICY AND PLANNING, AND IN COUNTRIES AND COMMUNITIES AROUND THE WORLD. WE HELP POLICYMAKERS UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH EFFORTS. IN 2018, PATH LED ADVOCACY EFFORTS TO ENSURE SUPPORT AMONG POLICYMAKERS IN THE UNITED STATES AND EUROPE FOR RESEARCH AND DEVELOPMENT, MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND GLOBAL HEALTH SECURITY. ONE EXAMPLE OF OUR SUCCESS WAS PASSAGE OF TWO POLICIES IN THE UNITED STATES THAT SOLIDIFIED US GOVERNMENT SUPPORT FOR RESEARCH AND DEVELOPMENT IN ITS GLOBAL HEALTH PROGRAMS. THANKS IN PART TO PATH'S EFFORTS TO EDUCATE MEMBERS OF CONGRESS, US GOVERNMENT FUNDING WAS MAINTAINED OR INCREASED FOR MATERNAL AND CHILD HEALTH, IMMUNIZATION, AND GLOBAL HEALTH RESEARCH AND DEVELOPMENT PROGRAMS.WORKING WITH PARTNERS IN AFRICAN COUNTRIES, WE HELPED ADVANCE POLICIES TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN. AMONG MANY ACHIEVEMENTS DURING 2018, IN KENYA, YEARS OF ADVOCACY BY PATH RESULTED IN PASSAGE OF THE FIRST COMPREHENSIVE POLICY THAT HARMONIZES DELIVERY OF HEALTH CARE FOR CHILDREN FROM BIRTH THROUGH ADOLESCENCE. IN THE DRC, A NATIONAL STRATEGY AND A SUBNATIONAL POLICY WERE ADOPTED TO PRIORITIZE ELIMINATION OF HUMAN AFRICAN TRYPANOSOMIASIS, ALSO KNOWN AS SLEEPING SICKNESS. IN SOUTH AFRICA, PATH'S ADVOCACY INFLUENCED THE PRIORITIZATION OF RESEARCH AND DEVELOPMENT FOR HEALTH IN A NATIONAL POLICY FOR SCIENCE, TECHNOLOGY, AND INNOVATION. AND IN UGANDA, PATH SUCCESSFULLY ADVOCATED FOR FUNDS TO BE ALLOCATED FOR VACCINE DISTRIBUTION.SPECIAL INITIATIVES:PATH IS ENGAGED IN A VARIETY OF SPECIAL INITIATIVES THAT GALVANIZE OUR EXPERTISE AND RESOURCES AND THOSE OF OUR GLOBAL PARTNERS TO SAVE MORE LIVES, MORE QUICKLY. BY THE END OF 2018, WE HAD ACTIVE HEALTH IMPACT TEAMS IN SEVEN HEALTH AREAS: MALARIA; HIV/AIDS; MATERNAL, NEWBORN, AND CHILD HEALTH; NUTRITION; SEXUAL AND REPRODUCTIVE HEALTH; EPIDEMIC PREPAREDNESS AND RESPONSE/GLOBAL HEALTH SECURITY INNOVATION; AND HEALTH SYSTEMS STRENGTHENING/PRIMARY HEALTH CARE. EACH HEALTH IMPACT TEAM GOES THROUGH A STAGED PROCESS OF SCALE-UP AND GROWTH. THESE TEAMS DEVELOP AND EVOLVE STRATEGY, STRENGTHEN AND CONNECT PATH TALENT ACROSS GEOGRAPHIES AND PROGRAMS, AND FOCUS ON REVENUE GENERATION FOR PATH THROUGH EXTERNAL ENGAGEMENT AND POSITIONING WITH KEY PARTNERS AND DONORS. 25764391 5244395 268781059 1 1 0 1 0 0 0 0 0 1 1 0 0 0 0 0 0 1 0 1 1 1 0 0 0 0 0 1 1 1 0 0 0 0 0 0 0 0 1 0 0 0 0 1 1 1 0 0 1 X 230 0 1 787 1 1 1 1 BE CH CG ET GH IN KE BM MZ PE SG SF SZ TZ UG UK UP VM ZA 0 0 0 0 0 0 0 0 0 0 X 14 14 0 0 0 0 0 0 0 1 1 0 0 1 1 1 1 1 1 1 1 0 AL AR CA CT FL IL KS KY MA MD MI MN MS NC NH NJ NM NY OK OR PA RI SC TN UT VA WI WV X X BRIAN NEVILLE CHIEF OF ACCOUNTING 2062853500 2201 WESTLAKE AVE SUITE 200 SEATTLE WA 98121 DAVID KING CHAIR 2.00 0.00 X X 0 0 0 FELIX OLALE VICE CHAIR 2.00 0.00 X X 0 0 0 YEHONG ZHANG SECRETARY 2.00 0.00 X X 0 0 0 BRUCE MCNAMER TREASURER 2.00 0.00 X X 0 0 0 DEAN ALLEN DIRECTOR 2.00 0.00 X 0 0 0 PEGGY JOHNSON DIRECTOR (UNTIL 12/2018) 2.00 0.00 X 0 0 0 GARY LOCKE DIRECTOR 2.00 0.00 X 0 0 0 JO ADDY DIRECTOR 2.00 0.00 X 0 0 0 IREENA VITTAL DIRECTOR 2.00 0.00 X 0 0 0 DEANNA OPPENHEIMER DIRECTOR 2.00 0.00 X 0 0 0 JOEL HOLSINGER DIRECTOR 2.00 0.00 X 0 0 0 JOHN-ARNE ROTTINGEN DIRECTOR 2.00 0.00 X 0 0 0 HELENA WAYTH DIRECTOR (BEGAN 6/2018) 2.00 0.00 X 0 0 0 TSITSI MASIYIWA DIRECTOR (UNTIL 3/2018) 2.00 0.00 X 0 0 0 DENNIS SCHMATZ DIRECTOR (UNTIL 3/2018) 2.00 0.00 X 0 0 0 BETH GALETTI DIRECTOR (BEGAN 12/2018) 2.00 0.00 X 0 0 0 SANFORD MELZER DIRECTOR (BEGAN 12/2018) 2.00 0.00 X 0 0 0 STEPHEN B DAVIS PRESIDENT AND CEO 38.00 2.00 X 665877 0 62780 OLIVIA D POLIUS CHIEF FINANCIAL OFFICER 38.00 2.00 X 320646 0 51936 DANIEL LASTER COO AND GENERAL COUNSEL 38.00 2.00 X 310669 0 41544 DAVID C KASLOW VP - PRODUCT DEVELOPMENT 38.00 2.00 X 379045 0 65678 AMIE E BATSON CHIEF STRATEGY OFFICER 39.00 1.00 X 378150 0 22577 KATHY CAHILL VP - INTERNATIONAL DEVELOPMENT 40.00 0.00 X 345013 0 26620 DAVID W FLEMING VP - PUBLIC HEALTH IMPACT 40.00 0.00 X 286869 0 50611 KATHRYN A O'DRISCOLL CHIEF HUMAN RESOURCES OFFICER 40.00 0.00 X 279820 0 27714 ERICA J SESSLE CHIEF OF STAFF 40.00 0.00 X 214378 0 34734 PRAVEEN RAJA VP - TECH. DEV. & INNOVATION 40.00 0.00 X 333003 0 31412 ELAINE L GIBBONS VP - GLOBAL ENGAGEMENT 40.00 0.00 X 265826 0 65813 JEFFREY D BERSON ASSOCIATE DIRECTOR II 40.00 0.00 X 431451 0 82104 JAMES B MCKENNA ASSOCIATE DIRECTOR II 40.00 0.00 X 396308 0 75232 TRAD M HATTON CHIEF OF PARTY 40.00 0.00 X 321206 0 48784 BRUCE LAMONT INNIS GLOBAL DISEASE AREA HEAD 40.00 0.00 X 311376 0 26645 JOHN O KONZ GLOBAL INT. PORT/FIN MGMT. CVIA HEAD 40.00 0.00 X 299215 0 64603 5538852 0 778787 340 0 1 0 WIDENET CONSULTING GROUP LLC 2910 1ST AVE S 200 SEATTLE WA 98134 CONSULTING 821832 RANDSTAD INDIA PVT LTD BLDG 9 STES 001/002 JASOLA NEW DELHI IN 110025 STAFFING SERVICES 715744 WMBE PAYROLLING DBA TARGET CW 9475 CHESAPEAKE DRIVE SAN DIEGO CA 92123 GENERAL CONTRACTOR 564411 SLALOM LLC 821 2ND AVE SUITE 1900 SEATTLE WA 98104 CONSULTING 488798 UNIFY CONSULTING LLC 1518 1ST AVE S STE 201 SEATTLE WA 98134 CONSULTING 471870 51 23547825 112897926 168869470 259914 305315221 CONSULTANCIES 541900 1500 1500 1500 2963587 2963587 78640623 547000 78565632 548448 74991 -1448 73543 73543 OTHER 900099 884888 884888 REIMBURSEMENTS 900099 95672 95672 980560 309334411 1500 0 4017690 20575733 20575733 9313 9313 42177100 42177100 4260713 309550 3899884 51279 102073963 74628680 26015749 1429534 10426617 10426617 16197399 1718558 14478841 6586983 3707 6583276 394432 171093 223097 242 331915 33164 298751 26000 12000 14000 207672 207672 20027156 13543689 6447874 35593 165753 90386 7269 68098 8810563 7390713 1376052 43798 732838 219457 465295 48086 381001 202061 178910 30 12048542 389297 11659245 19986534 18565722 1358161 62651 8333110 8022756 269979 40375 8819 8819 2974173 3101 2971072 725361 187114 538247 SUBCONTRACTS 24705297 23525529 1132123 47645 EQUIP RENT & MAINT 3443347 2203342 1236793 3212 LEAVE & BENS ALLOC 0 36911256 -37679297 768041 FACILITIES ALLOC 0 12623474 -12990044 366570 7156135 5264264 1670390 221481 312766469 268781059 40798775 3186635 3035980 7576050 3493254 14017223 254454281 35571476 13578928 10652789 4753758 5307245 36534903 25486998 11878205 11047905 176133425 153328545 619867 0 467947698 237501233 50220817 202736996 576675 194878 50797492 202931874 X 25292293 19811400 388460737 14757959 3397176 0 417150206 34569359 467947698 237501233 X -3432058 -393146 -378755643 X 0 1 X 1 1 1 X 286891535 243499792 298315988 347844394 305316107 1481867816 286891535 243499792 298315988 347844394 305316107 1481867816 647466981 834400835 1370599 1471233 1797794 2050888 2963587 9654101 38502 38502 763131 2551502 4668393 5225302 980560 14188888 1505749307 250697 0.55410 0.59120 X RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED RESTRICTED 7856 217088 224944 311815894 312040838 1000000 250000 0 0 1000000 1000000 1000000 1000000 4000000 6000000 156961 168991 294096 224944 844992 250000 250000 250000 250000 1000000 1500000 14461 470 127336 7856 150123 10056545 1240 -494491 467377 9095917 9339249 3410 1159282 445396 10056545 8897224 4256 907978 470209 9339249 9404188 2665 -58783 450846 8897224 9016994 9350 768184 390340 9404188 0.36000 0.37000 0.27000 0 0 20479518 13086483 7393035 10835427 8231189 2604238 5219958 4169326 1050632 11047905 PART V, LINE 4: IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY, PATH UTILIZES THE INCOME EARNED ON THE ENDOWMENT FUNDS AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH. 1 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 14826 CENTRAL AMERICA AND THE CARIBBEAN 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 979 CENTRAL AMERICA AND THE CARIBBEAN 0 0 GRANTMAKING 380632 EAST ASIA AND THE PACIFIC 4 89 MANAGEMENT & GENERAL 1040096 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 4441155 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 310893 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 79330 EAST ASIA AND THE PACIFIC 0 0 PROGRAM SERVICES OTHER 2940 EAST ASIA AND THE PACIFIC 0 0 FUNDRAISING 68916 EAST ASIA AND THE PACIFIC 0 0 GRANTMAKING 4746774 EUROPE 1 6 MANAGEMENT & GENERAL 20005 EUROPE 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 1565902 EUROPE 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 4020990 EUROPE 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 205993 EUROPE 0 0 PROGRAM SERVICES OTHER 3105 EUROPE 0 0 FUNDRAISING 11452 EUROPE 0 0 GRANTMAKING 23522629 MIDDLE EAST AND NORTH AFRICA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 218 NORTH AMERICA 0 0 MANAGEMENT & GENERAL 56482 NORTH AMERICA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 121949 NORTH AMERICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 194221 NORTH AMERICA 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 44284 NORTH AMERICA 0 0 GRANTMAKING 733350 RUSSIA AND NEIGHBORING STATES 1 24 MANAGEMENT & GENERAL 295153 RUSSIA AND NEIGHBORING STATES 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 2753844 RUSSIA AND NEIGHBORING STATES 0 0 GRANTMAKING 1133768 SOUTH AMERICA 1 3 MANAGEMENT & GENERAL 48946 SOUTH AMERICA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 402511 SOUTH AMERICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 2836 SOUTH AMERICA 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 3228 SOUTH AMERICA 0 0 PROGRAM SERVICES OTHER 34 SOUTH AMERICA 0 0 GRANTMAKING 138891 SOUTH ASIA 4 91 MANAGEMENT & GENERAL 1420932 SOUTH ASIA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 3526336 SOUTH ASIA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 493818 SOUTH ASIA 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 617215 SOUTH ASIA 0 0 PROGRAM SERVICES OTHER 11038 SOUTH ASIA 0 0 GRANTMAKING 1886168 SUB-SAHARAN AFRICA 36 817 MANAGEMENT & GENERAL 10173517 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES GLOBAL HEALTH PROGRAM 54325843 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES ESSENTIAL MEDICINE 1037175 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 1003695 SUB-SAHARAN AFRICA 0 0 PROGRAM SERVICES OTHER 1581091 SUB-SAHARAN AFRICA 0 0 FUNDRAISING 12972 SUB-SAHARAN AFRICA 0 0 GRANTMAKING 9634888 4 89 43 941 47 1030 6270851 125820169 132091020 CENTRAL AMERICA & THE CARIBBEAN GLOBAL HEALTH PROGRAMS 150305 CHECK/WIRE CENTRAL AMERICA & THE CARIBBEAN GLOBAL HEALTH PROGRAMS 230327 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 5056 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 5855 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 6014 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 6316 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 6683 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 7428 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 7496 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 8651 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 8726 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 8831 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 17290 CHECK/WIRE EAST ASIA & THE PACIFIC TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 18465 CHECK/WIRE EAST ASIA & THE PACIFIC ESSENTIAL MEDICINE 18988 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 20165 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 20651 CHECK/WIRE EAST ASIA & THE PACIFIC ESSENTIAL MEDICINE 30000 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 36845 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS & ESSENTIAL MEDICINE 41922 CHECK/WIRE EAST ASIA & THE PACIFIC ESSENTIAL MEDICINE 51551 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 52029 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 54779 CHECK/WIRE EAST ASIA & THE PACIFIC TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 63761 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 72805 CHECK/WIRE EAST ASIA & THE PACIFIC TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 88594 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 100267 CHECK/WIRE EAST ASIA & THE PACIFIC ESSENTIAL MEDICINE 124235 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 174483 CHECK/WIRE EAST ASIA & THE PACIFIC ESSENTIAL MEDICINE 210000 CHECK/WIRE EAST ASIA & THE PACIFIC GLOBAL HEALTH PROGRAMS 340199 CHECK/WIRE EAST ASIA & THE PACIFIC ESSENTIAL MEDICINE 906750 CHECK/WIRE EAST ASIA & THE PACIFIC ESSENTIAL MEDICINE 2220200 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 5487 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 15000 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 20000 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 42190 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 47584 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 91299 CHECK/WIRE EUROPE TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 95018 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 100000 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 110493 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS 125000 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 184850 CHECK/WIRE EUROPE TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 258278 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 260000 CHECK/WIRE EUROPE TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 330632 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 331139 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS & TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 350000 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS & ESSENTIAL MEDICINE 672105 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 858186 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 1127499 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 1636289 CHECK/WIRE EUROPE ESSENTIAL MEDICINE 13537059 CHECK/WIRE EUROPE GLOBAL HEALTH PROGRAMS, ESSENTIAL MEDICINE, TECHNOLOGY, ANALYTICS AND MARKET INNOVATION, AND OTHER 3321058 CHECK/WIRE NORTH AMERICA ESSENTIAL MEDICINE 38669 CHECK/WIRE NORTH AMERICA ESSENTIAL MEDICINE 133260 CHECK/WIRE NORTH AMERICA ESSENTIAL MEDICINE 561421 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 15822 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 17708 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 17925 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 21417 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 23824 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 28182 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 30506 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 33192 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 36049 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 39440 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 40919 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 44199 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 55632 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 72476 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 89186 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 114306 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 115520 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 148673 CHECK/WIRE RUSSIA & NEIGHBORING STATES GLOBAL HEALTH PROGRAMS 188791 CHECK/WIRE SOUTH AMERICA GLOBAL HEALTH PROGRAMS 20000 CHECK/WIRE SOUTH AMERICA TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 32890 CHECK/WIRE SOUTH AMERICA GLOBAL HEALTH PROGRAMS 86001 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 5524 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 10449 CHECK/WIRE SOUTH ASIA TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 15000 CHECK/WIRE SOUTH ASIA TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 23210 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 40450 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 54148 CHECK/WIRE SOUTH ASIA TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 70000 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE & TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 76827 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 85762 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 189652 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 300000 CHECK/WIRE SOUTH ASIA ESSENTIAL MEDICINE 461944 CHECK/WIRE SOUTH ASIA GLOBAL HEALTH PROGRAMS 553203 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 6044 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 6663 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 6731 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 7853 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 10474 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 10577 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 10653 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 10742 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 11068 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 11364 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 12207 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 12240 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 12567 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 12698 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 12773 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 13336 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 13567 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 13740 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 13937 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 14232 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 14345 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 14403 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 14423 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 14444 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 14548 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 14596 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 14786 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 14828 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 14913 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 14941 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 15024 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 15232 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 15475 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 15706 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 17894 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 19200 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 20424 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 20918 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 21623 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 21769 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 22301 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 23061 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 23327 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 24586 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 24953 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 25222 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 27010 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 27314 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 27323 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 28097 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 28185 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 28842 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 29409 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 29615 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 30553 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 33176 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 37570 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 37612 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 38771 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 39283 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 42015 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 42522 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 42821 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 45000 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 45005 CHECK/WIRE SUB-SAHARAN AFRICA TECHNOLOGY, ANALYTICS AND MARKET INNOVATION 49896 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 50367 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 51041 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 51721 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 53203 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 53323 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 61616 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 70705 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS & ESSENTIAL MEDICINE 86825 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 90313 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 92565 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 94051 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 94299 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 109395 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 116943 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 136668 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 143568 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 154101 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 199361 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 289929 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 328475 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 372808 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 386133 CHECK/WIRE SUB-SAHARAN AFRICA GLOBAL HEALTH PROGRAMS 1520852 CHECK/WIRE SUB-SAHARAN AFRICA ESSENTIAL MEDICINE 3632614 CHECK/WIRE 132 50 1 0 0 0 0 0 PART I, LINE 2: PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. 1 GLOBAL HEALTH CORPS 318 WEST 39TH STREET ROOM 9L NEW YORK NY 10018 800512336 501(C)(3) 6456 GLOBAL HEALTH PROGRAMS MANAGEMENT SCIENCES FOR HEALTH 200 RIVERS EDGE DRIVE SUITE 320 MEDFORD MA 02155 042482188 501(C)(3) 9967 GLOBAL HEALTH PROGRAMS VAYU INC 847 WILLOW RUN AIRPORT DR YPSILANTI MI 48198 465737909 N/A 10000 TECHNOLOGY, ANALYTICS AND MARKET INNOVATION JHPIEGO 1615 THAMES STREET SUITE 200 BALTIMORE MD 212313447 237424444 501(C)(3) 15000 GLOBAL HEALTH PROGRAMS TECHCHANGE INC 2001 13TH ST NW 2ND FLOOR WASHINGTON DC 20009 273358772 N/A 16500 GLOBAL HEALTH PROGRAMS UNIVERSITY OF MIAMI MED CAMPUS PO BOX 016960 M-859 MIAMI FL 33101 590624458 501(C)(3) 17108 ESSENTIAL MEDICINE UNIVERSITY OF MASSACHUSETTS MEDICAL SCHOOL 55 LAKE AVE NORTH WORCESTER MA 01655 043167352 GOV 20000 ESSENTIAL MEDICINE BENEVOLENT HEALTHCARE FOUNDATION DBA PROJECT CURE 10377 E GEDDES AVENUE SUITE 200 CENTENNIAL CO 80112 841568566 501(C)(3) 28597 GLOBAL HEALTH PROGRAMS MEDICAL CARE DEVELOPMENT INC 11 PARKWOOD DRIVE AUGUSTA ME 04330 016022787 501(C)(3) 28973 GLOBAL HEALTH PROGRAMS ROSTROPOVICH-VISHNEVSKAYA FOUNDATION 1776 K STREET NW SUITE 700 WASHINGTON DC 20006 521752473 501(C)(3) 29244 ESSENTIAL MEDICINE UNIVERSITY OF SOUTH FLORIDA 4202 EAST FOWLER AVENUE ALN 147 TAMPA FL 33620 593102112 GOV 29628 ESSENTIAL MEDICINE AMREF HEALTH AFRICA INC 4 WEST 43RD STREET 2ND FLOOR NEW YORK NY 10036 131867411 501(C)(3) 33772 GLOBAL HEALTH PROGRAMS SEATTLE CHILDREN'S HOSPITAL PO BOX 5371 M/S RC-507 SEATTLE WA 981455005 910564748 501(C)(3) 39739 TECHNOLOGY, ANALYTICS AND MARKET INNOVATION THE WILLIAM DAVIDSON INST AT THE UNIV OF MICHIGAN (WDI) 724 E UNIVERSITY AVE WYLY HALL FIRST FLOOR ANN ARBOR MI 48109 383048086 501(C)(3) 42923 GLOBAL HEALTH PROGRAMS PARSYL INC 3963 WALNUT STREET STE 200 DENVER CO 80205 814027966 N/A 46400 TECHNOLOGY, ANALYTICS AND MARKET INNOVATION CARDNO EMERGING MARKETS 2107 WILSON BLVD STE 800 ARLINGTON VA 22201 521788060 N/A 57894 GLOBAL HEALTH PROGRAMS POPULATION SERVICES INT'L INC 1120 19TH ST NW STE 600 WASHINGTON DC 20036 560942853 501(C)(3) 59381 GLOBAL HEALTH PROGRAMS GHP SOLUTIONS LLC 220 EAST 42ND STREET SUITE 710 NEW YORK NY 10017 061652595 N/A 61474 GLOBAL HEALTH PROGRAMS SOLAR ELECTRIC LIGHT FUND 1612 K STREET NW SUITE 300 WASHINGTON DC 20006 521701564 501(C)(3) 66402 TECHNOLOGY, ANALYTICS AND MARKET INNOVATION PAN AMERICAN HEALTH ORGANIZATION 525 23RD STREET NW WASHINGTON DC 20037 237072046 501(C)(3) 67799 GLOBAL HEALTH PROGRAMS UNIVERSITY OF MARYLAND PO BOX 41428 BALTIMORE MD 212036428 526002033 501(C)(3) 69971 ESSENTIAL MEDICINE THE UNIVERSITY OF TEXAS AT AUSTIN 110 INNER CAMPUS DRIVE STOP K5300 AUSTIN TX 78712 746000203 GOV 80000 ESSENTIAL MEDICINE OPENMRS INC 10425 COMMERCE DR STE 110 CARMEL IN 460327643 455316647 501(C)(3) 88500 GLOBAL HEALTH PROGRAMS HENRY M JACKSON FOUNDATION FOR THE ADVANCEMENT OF MILITARY MEDICINE INC 6720-A ROCKLEDGE DRIVE STE 100 BETHESDA MD 20817 521317896 501(C)(3) 89999 ESSENTIAL MEDICINE BASIC HEALTH INTERNATIONAL INC 25 BROADWAY 10TH FLOOR NEW YORK NY 10004 203408717 501(C)(3) 93074 GLOBAL HEALTH PROGRAMS THE ALBERT B SABIN VACCINE INSTITUTE INC 2175 K STREET NW SUITE 400 WASHINGTON DC 20037 061389829 501(C)(3) 100000 ESSENTIAL MEDICINE FOOD AND DRUG ADMINISTRATION 5600 FISHERS LN HFA-140 RM 11-40 ROCKVILLE MD 20857 530196965 GOV 110500 ESSENTIAL MEDICINE HEALTH ALLIANCE INTERNATIONAL 4534 11TH AVENUE NE SEATTLE WA 98105 943047981 501(C)(3) 118329 GLOBAL HEALTH PROGRAMS QUALIS HEALTH 10700 MERIDIAN AVE N SUITE 100 SEATTLE WA 98133 911072875 501(C)(3) 127144 GLOBAL HEALTH PROGRAMS KYBELE INC 3524 YADKINVILLE ROAD 124 WINSTONSALEM NC 27106 900759003 501(C)(3) 133219 GLOBAL HEALTH PROGRAMS MASSACHUSETTS INSTITUTE OF TECHNOLOGY 77 MASSACHUSETTS AVENUE CAMBRIDGE MA 02139 042103594 501(C)(3) 140000 ESSENTIAL MEDICINE UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE 85 SOUTH PROSPECT STREET BURLINGTON VT 05405 030179440 501(C)(3) 141493 ESSENTIAL MEDICINE ACESO GLOBAL 1400 16TH STREET NW SUITE 430 WASHINGTON DC 20036 474215911 501(C)(3) 145548 GLOBAL HEALTH PROGRAMS HJF MEDICAL RESEARCH INTERNATIONAL INC 6720A ROCKLEDGE DRIVE SUITE 100 BETHESDA MD 20817 522322791 501(C)(3) 136117 GLOBAL HEALTH PROGRAMS HEIFER INTERNATIONAL DC 1 WORLD AVENUE LITTLE ROCK AR 72202 351019477 501(C)(3) 158702 TECHNOLOGY, ANALYTICS AND MARKET INNOVATION MASSACHUSETTS GENERAL HOSPITAL ED ZERO EMERSON PL 104 BOSTON MA 02114 041564655 501(C)(3) 175000 ESSENTIAL MEDICINE ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION AIDS FOUNDATION 1140 CONNECTICUT AQG NW 200 WASHINGTON DC 20036 954191698 501(C)(3) 223762 GLOBAL HEALTH PROGRAMS SEATTLE BIOMEDICAL RESEARCH INSTITUTE INSTITUTE 307 WESTLAKE AVE N SUITE 500 SEATTLE WA 981095219 910961784 501(C)(3) 226438 ESSENTIAL MEDICINE HARVARD UNIVERSITY 1033 MASSACHUSETTS AVE 2ND FLOOR CAMBRIDGE MA 02115 042103580 501(C)(3) 233379 GLOBAL HEALTH PROGRAMS & ESSENTIAL MEDICINE TULANE UNIVERSITY 6823 ST CHARLES AQGE NEW ORLEANS LA 70112 720423889 501(C)(3) 235475 GLOBAL HEALTH PROGRAMS THE STATE UNIVERSITY OF NEW ANORK 35 STATE STREET ALBANY NY 122072826 141368361 501(C)(3) 292383 ESSENTIAL MEDICINE BRIGHAM & WOMEN'S HOSPITAL INC 651 HUNTINGTON AVE FXB BUILDING BOSTON MA 02115 042312909 501(C)(3) 302658 GLOBAL HEALTH PROGRAMS CASCADE DESIGNS INC 4000 1ST AVE SOUTH SEATTLE WA 98134 910969695 N/A 315000 TECHNOLOGY, ANALYTICS AND MARKET INNOVATION FINA BIOSOLUTIONS LLC 9430 KEY WEST AVE SUITE 200 ROCKVILLE MD 20850 205448275 N/A 321231 ESSENTIAL MEDICINE HARVARD SCHOOL OF PUBLIC HEALTH 677 HUNTINGTON AVENUE BOSTON MA 02215 042103580 501(C)(3) 374803 ESSENTIAL MEDICINE DUKE UNIVERSITY BOX 104132 DURHAM NC 27708 560532129 501(C)(3) 397629 ESSENTIAL MEDICINE INITIATIVES INC 264 BEACON STREET BOSTON MA 02116 042961350 N/A 399082 GLOBAL HEALTH PROGRAMS CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER 3333 BURNET AVE ML 6014 CINCINNATI OH 452293039 310833936 501(C)(3) 415954 ESSENTIAL MEDICINE US NAVAL MEDICAL RESEARCH UNIT NO 3 NAMRU-3 503 ROBERT GRANT AVE BLDG500 SILVER SPRING MD 20901 470100048 GOV 434441 ESSENTIAL MEDICINE RESULTS FOR DEVELOPMENT INSTITUTE INC 1100 15TH STREET NW SUITE 400 WASHINGTON DC 20005 208530747 501(C)(3) 452200 GLOBAL HEALTH PROGRAMS EHEALTH AFRICA 1200 G ST NW SUITE 800 WASHINGTON DC 20005 814503438 501(C)(3) 482335 GLOBAL HEALTH PROGRAMS POPULATION COUNCIL ONE DAG HAMMERKJOLD PLAZA NEW YORK NY 10017 131687001 501(C)(3) 535709 TECHNOLOGY, ANALYTICS AND MARKET INNOVATION INTRAHEALTH INTERNATIONAL INC 6340 QUADRANGLE DRIVE SUITE 200 CHAPEL HILL NC 27517 550825466 501(C)(3) 574134 GLOBAL HEALTH PROGRAMS SYSTMAPP INC 2000 TOWN CENTER SUITE 300 SOUTHFIELD MI 48075 812936844 N/A 600000 GLOBAL HEALTH PROGRAMS VILLAGEREACH 2900 EASTLAKE AVE E SUITE 230 SEATTLE WA 981023012 912088484 501(C)(3) 687045 GLOBAL HEALTH PROGRAMS THE SCRIPPS RESEARCH INSTITUTE 10550 N TORREY PINES ROAD LA JOLLA CA 92037 330435954 501(C)(3) 756375 ESSENTIAL MEDICINE INVENTPRISE LLC 18133 NE 68TH STREET SUITE D 150 REDMOND WA 98052 454927373 N/A 789523 ESSENTIAL MEDICINE JOHNS HOPKINS UNIVERSITY BLOOMBERG SCHL OF PUB HLTH 615 N WOLFE STREET BALTIMORE MD 21205 520595110 501(C)(3) 831856 GLOBAL HEALTH PROGRAMS & ESSENTIAL MEDICINE UNIVERSITY OF WASHINGTON GRANT CONTRACT ACCOUNTING 12455 COLLECTIONS DRIVE CHICAGO IL 60693 916001537 501(C)(3) 1225899 GLOBAL HEALTH PROGRAMS, ESSENTIAL MEDICINE, & TECHNOLOGY, ANALYTICS AND MARKET INNOVATION BECTON DICKINSON & COMPANY ONE BECTON DRIVE FRANKLIN LAKES NJ 07417 N/A 1386791 TECHNOLOGY, ANALYTICS AND MARKET INNOVATION NAT'L INST OF ALLERGY & INFECTIOUS DISEASES 6610 ROCKLEDGE DR ROOM 2800 BETHESDA MD 208926606 520858115 GOV 1387280 ESSENTIAL MEDICINE JSI RESEARCH AND TRAINING INSTITUTE INC 1616 NORTH FORT MYER DR 16TH FLOOR ARLINGTON VA 222093100 042679824 N/A 1390705 GLOBAL HEALTH PROGRAMS WALTER REED ARMY INSTITUTE OF RESEARCH US TREASURY 503 ROBERT GRANT AVE SILVER SPRING MD 20910 520664528 GOV 2994916 ESSENTIAL MEDICINE YALE UNIVERSITY GRANT AND CONTRACT FINANCIAL ADMIN PO BOX 1873 NEW HAVEN CT 065081873 060646973 501(C)(3) -182082 ESSENTIAL MEDICINE WORLD VISION PO BOX 9716 DPTW FEDERAL WAY WA 980639716 951922279 501(C)(3) -86473 GLOBAL HEALTH PROGRAMS HELEN KELLER INTERNATIONAL INC 352 PARK AVENUE SOUTH FLOOR 12 NEW YORK NY 10010 135562162 501(C)(3) -18449 GLOBAL HEALTH PROGRAMS 51 12 GRANT 1 9313 PART I, LINE 2: PATH HAS A SUBRECIPIENT POLICY AND PROCEDURES IN PLACE TO GUIDE THE WAY OUR PROJECT TEAMS MONITOR SUBRECIPIENTS. THIS INCLUDES BOTH FINANCIAL AND TECHNICAL MONITORING. PATH USES RISK ASSESSMENTS, REPORTING, SITE VISITS, REGULAR CONTACT, AND OTHER MEANS TO PROVIDE THE MONITORING REQUIRED BY FUNDERS AND TO ENSURE GOOD PROJECT STEWARDSHIP. THESE ACTIVITIES ALSO PROVIDE RESPONSIBLE ASSURANCE THAT THE SUBRECIPIENT ADMINISTERS FUNDS IN COMPLIANCE WITH LAWS, REGULATIONS, AND PRIME AWARD TERMS AND ACHIEVES PERFORMANCE GOALS. PATH HAS ESTABLISHED COMPREHENSIVE POLICIES AND PROCEDURES TO PROMOTE BEST BUSINESS PRACTICES AND ENSURE EFFICIENT AND EFFECTIVE INTERNAL CONTROL. THESE ARE COMBINED WITH AN INTERNAL AUDIT FUNCTION THROUGH WHICH PATH CONDUCTS AUDITS ON GRANT-FUNDED PROGRAMS TO ENSURE COMPLIANCE WITH REGULATORY REQUIREMENTS. X X 1 1 X X X X 1 0 0 0 0 0 0 1 0 STEPHEN B DAVIS PRESIDENT AND CEO 512010 0 152067 0 1800 0 32200 0 30580 0 728657 0 0 0 OLIVIA D POLIUS CHIEF FINANCIAL OFFICER 318546 0 0 0 2100 0 32400 0 19536 0 372582 0 0 0 DANIEL LASTER COO AND GENERAL COUNSEL 308869 0 0 0 1800 0 32400 0 9144 0 352213 0 0 0 DAVID C KASLOW VP - PRODUCT DEVELOPMENT 377245 0 0 0 1800 0 32400 0 33278 0 444723 0 0 0 AMIE E BATSON CHIEF STRATEGY OFFICER 194527 0 0 0 183623 0 21347 0 1230 0 400727 0 0 0 KATHY CAHILL VP - INTERNATIONAL DEVELOPMENT 195454 0 0 0 149559 0 23454 0 3166 0 371633 0 0 0 DAVID W FLEMING VP - PUBLIC HEALTH IMPACT 286869 0 0 0 0 0 32400 0 18211 0 337480 0 0 0 KATHRYN A O'DRISCOLL CHIEF HUMAN RESOURCES OFFICER 152146 0 0 0 127674 0 18452 0 9262 0 307534 0 0 0 ERICA J SESSLE CHIEF OF STAFF 212878 0 0 0 1500 0 23510 0 11224 0 249112 0 0 0 PRAVEEN RAJA VP - TECH. DEV. & INNOVATION 332163 0 0 0 840 0 20239 0 11173 0 364415 0 0 0 ELAINE L GIBBONS VP - GLOBAL ENGAGEMENT 264986 0 0 0 840 0 32400 0 33413 0 331639 0 0 0 JEFFREY D BERSON ASSOCIATE DIRECTOR II 170197 0 0 0 261254 0 24555 0 57549 0 513555 0 0 0 JAMES B MCKENNA ASSOCIATE DIRECTOR II 141788 0 0 0 254520 0 21650 0 53582 0 471540 0 0 0 TRAD M HATTON CHIEF OF PARTY 134488 0 0 0 186718 0 17173 0 31611 0 369990 0 0 0 BRUCE LAMONT INNIS GLOBAL DISEASE AREA HEAD 310536 0 0 0 840 0 27312 0 -667 0 338021 0 0 0 JOHN O KONZ GLOBAL INT. PORT/FIN MGMT. CVIA HEAD 298375 0 0 0 840 0 32400 0 32203 0 363818 0 0 0 PART I, LINE 1A HOUSING ALLOWANCES & TAX INDEMNIFICATIONS ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITIONS. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT. PART I, LINE 4A THE FOLLOWING EMPLOYEES RECEIVED SEVERANCE PAYMENTS IN 2018: - KATHRYN A. O'DRISCOLL $126,624 - AMIE BATSON $162,501 - KATHY CAHILL $143,503 PART I, LINE 7 BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). X 19 242558 FMV X SUPPLIES 3 17356 COST 0 0 1 0 PART I, COLUMN (B): THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS. FORM 990, PART I, LINE 1 PATH IS A GLOBAL ORGANIZATION THAT WORKS TO ACCELERATE HEALTH EQUITY BY BRINGING TOGETHER PUBLIC INSTITUTIONS, BUSINESSES, SOCIAL ENTERPRISES, AND INVESTORS TO SOLVE THE WORLD'S MOST PRESSING HEALTH CHALLENGES. WITH EXPERTISE IN SCIENCE, HEALTH, ECONOMICS, TECHNOLOGY, ADVOCACY, AND DOZENS OF OTHER SPECIALTIES, PATH DEVELOPS AND SCALES SOLUTIONS-INCLUDING VACCINES, DRUGS, DEVICES, DIAGNOSTICS, AND INNOVATIVE APPROACHES TO STRENGTHENING HEALTH SYSTEMS WORLDWIDE. SINCE 2011, PATH AND OUR PARTNERS AND SUPPORTERS HAVE REACHED AN AVERAGE OF MORE THAN 150 MILLION PEOPLE EACH YEAR WITH LIFESAVING HEALTH SOLUTIONS. FORM 990, PART III, LINE 4A PATH CONTINUED TO PILOT INNOVATIONS TO REACH MOST-AT-RISK POPULATIONS IN VIETNAM. WE EQUIPPED SOCIAL AND SUPPORT GROUPS OPERATED BY MEMBERS OF KEY POPULATIONS TO GENERATE DEMAND FOR SERVICES AMONG THEIR PEERS THROUGH TARGETED OUTREACH VIA SOCIAL MEDIA, LINKAGES TO HIV TESTING SERVICES THROUGH MOBILE APPLICATIONS, AND SCALE-UP OF HIV SELF-TESTING AND PREP. PATH ALSO ENGAGED THE GOVERNMENT OF VIETNAM TO INTRODUCE NEW MODELS OF HIV TESTING, INCLUDING EXPANDING ACCESS TO HIV LAY- AND SELF-TESTING AND PARTNER NOTIFICATION SERVICES, INTRODUCING AND SCALING FEE-BASED PREP, LAUNCHING THREE LOCAL CONDOM BRANDS MARKETED FOR KEY POPULATIONS, AND DEVELOPING BETTER LOW-DEAD-SPACE SYRINGES FOR PEOPLE WHO INJECT DRUGS. PATH ALSO BRINGS GLOBAL HEALTH EXPERTISE AND INNOVATIVE APPROACHES TO THE FIGHT AGAINST TB. WE WORK DIRECTLY WITH PUBLIC- AND PRIVATE-SECTOR LABORATORIES TO STRENGTHEN CAPACITY TO QUICKLY DIAGNOSE DRUG-SUSCEPTIBLE, MULTIDRUG-RESISTANT, AND EXTENSIVELY DRUG-RESISTANT TB PATIENTS. WE ALSO SUPPORT FACILITIES AND LABORATORIES WITH INFRASTRUCTURE, SUCH AS SOLAR PANELS AND COMPUTER SYSTEMS, TO RUN TB DIAGNOSTIC EQUIPMENT AND ENSURE A SUSTAINABLE PLAN FOR MAINTENANCE AND CARE. IN UKRAINE, PATH LED THE USAID-FUNDED SERVING LIFE PROJECT, WORKING TO REDUCE TB, HIV, AND HEPATITIS C TRANSMISSION IN PRE-TRIAL DETENTION CENTERS, PRISONS, POST-PRISON SETTINGS, AND THE COMMUNITY. STRATEGIES INCLUDED INCREASING CASE DETECTION, STRENGTHENING LINKAGES TO CARE, AND EMPLOYING A CASE-MANAGEMENT APPROACH TO ENSURE THAT INSTITUTIONALIZED OR COMMUNITY-BASED KEY POPULATIONS WHO HAVE TB, HIV, OR HEPATITIS C CAN COMPLETE TREATMENT. IN A RELATED EFFORT, PATH PARTNERED WITH THE MINISTRY OF JUSTICE TO ENSURE THAT ALL NEWLY INCARCERATED INDIVIDUALS ARE ROUTINELY SCREENED FOR TB UPON ENTRY, ANNUALLY, AND PRIOR TO RELEASE, AND THAT THOSE CONFIRMED WITH ACTIVE TB RECEIVE TREATMENT DURING INCARCERATION OR A REFERRAL TO A TB TREATMENT FACILITY AFTER RELEASE. UNDER THE USAID-FUNDED ERADICATE TB PROJECT IN ZAMBIA, PATH ENGAGED DIRECTLY WITH PRISON ADMINISTRATORS TO PROMOTE TB SCREENING UPON ENTRY, ANNUALLY, AND PRIOR TO RELEASE. IN TANZANIA, UNDER THE CHALLENGE TB PROJECT, PATH STRENGTHENED THE CAPACITY OF SIX CIVIL-SOCIETY ORGANIZATIONS TO PROVIDE COMMUNITY-BASED TB TREATMENT ADHERENCE SUPPORT. PATH ALSO DEVELOPED A TREATMENT ADHERENCE APP THAT SENDS TREATMENT AND APPOINTMENT REMINDERS TO PEOPLE WITH TB VIA TEXT MESSAGE. AFTER ITS LAUNCH IN SEPTEMBER 2018, MORE THAN 7,500 PEOPLE ENROLLED IN THE APP. IN ADDITION, PATH DEVELOPED AND LAUNCHED A SELF-SCREENING APP TO RAISE AWARENESS ABOUT TB AND INCREASE TB CASE DETECTION. THOSE WHO SELF-REPORT AS PRESUMPTIVE FOR TB RECEIVE REFERRAL MESSAGES TO GO TO A NEARBY HEALTH FACILITY FOR CONFIRMATORY TESTING. IN INDIA, WE CONTINUED TO IMPLEMENT THE PUBLIC-PRIVATE INTERFACE AGENCY (PPIA) PROJECT TO IMPROVE PRIVATE HEALTH CARE PROVIDERS' CONTRIBUTIONS TO TB CONTROL ACROSS 15 WARDS IN THE URBAN SLUMS OF MUMBAI. IN 2018, THE PROJECT FURTHER ENGAGED WITH FORMAL AND INFORMAL PRACTITIONERS, LABORATORIES, CHEMISTS, AND HOSPITALS TO PROVIDE STANDARDIZED TB DIAGNOSIS AND TREATMENT SERVICES. PATH ALSO SUPPORTED A VOUCHER MECHANISM TO CONNECT PATIENTS FROM LOCAL INFORMAL PROVIDERS TO QUALIFIED PHYSICIANS, DIAGNOSTIC SERVICES, AND TREATMENT SUPPORT. THE PROJECT HAS DRAMATICALLY IMPROVED ACCESS TO TB SERVICES. THE BREATH FOR LIFE PROJECT IN VIETNAM DEVELOPED AND TESTED A MODEL THAT ADDRESSES HEALTH SYSTEM CHALLENGES CONTRIBUTING TO LOW DETECTION OF TB AMONG CHILDREN. OUR EFFORTS THROUGH THIS PROJECT RESULTED IN DECENTRALIZED PEDIATRIC TB DIAGNOSIS AND TREATMENT, A DOUBLING OF TB DIAGNOSIS AMONG CHILDREN, AND A FOURFOLD INCREASE IN ELIGIBLE CHILDREN ON TB PREVENTIVE THERAPY. BUILDING ON OUR PEDIATRIC WORK UNDER BREATH FOR LIFE, PATH COORDINATED WITH THE ZAMBIA MINISTRY OF HEALTH IN 2018 TO FINALIZE CHILDHOOD TB TRAINING MATERIALS. MEASUREMENT AND LEARNING CONTINUED TO SERVE AS CORNERSTONES FOR PATH'S TB PROGRAMMING. UNDER THE ERADICATE TB PROJECT IN ZAMBIA, PATH COORDINATED WITH THE MINISTRY OF HEALTH AND NATIONAL TUBERCULOSIS AND LEPROSY CONTROL PROGRAM TO UPDATE THEIR MONITORING SYSTEMS, INCLUDING SECONDING A MONITORING AND EVALUATION (M&E) ADVISOR WHO PROVIDES ON-SITE MENTORSHIP TO NATIONAL-LEVEL GOVERNMENT OFFICIALS TO ANALYZE DATA FOR PROGRAMMATIC DECISION-MAKING. IN INDIA, PATH DEVELOPED M&E AND REPORTING GUIDELINES FOR PUBLIC-PRIVATE MIX NETWORKS AND PROVIDED DIRECT TECHNICAL ASSISTANCE TO THE GOVERNMENT TO STRENGTHEN CAPACITY IN DATA ANALYSIS AND USE. IN VIETNAM, PATH HELPED THE MINISTRY OF HEALTH TO INTEGRATE PUBLIC-PRIVATE MIX AND PEDIATRIC TB DATA-CAPTURE INTO NATIONAL M&E SYSTEMS. MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION PATH WORKS WITH PARTNERS TO IMPROVE MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION AROUND THE WORLD. TOGETHER WE DEVELOP, ADAPT, AND SCALE TECHNOLOGIES AND APPROACHES TO REDUCE ILLNESS AND DEATH AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. IN ALL OUR EFFORTS, WE PUT THE LOCAL GOVERNMENT IN THE DRIVER'S SEAT TO ENSURE BOTH SCALE AND SUSTAINABILITY. IN 2018, PATH CONTINUED TO EXPAND OUR GLOBAL AND NATIONAL LEADERSHIP IN EARLY CHILDHOOD DEVELOPMENT (ECD). WITH PATH'S SUPPORT, THE GOVERNMENTS OF ETHIOPIA, KENYA, MOZAMBIQUE, AND ZAMBIA INCORPORATED ECD SERVICES INTO BASIC HEALTH CARE FOR CAREGIVERS AND YOUNG CHILDREN. ALONG WITH WHO, UNICEF, THE WORLD BANK, AND OTHERS, PATH ALSO CONTRIBUTED TO THE DEVELOPMENT, LAUNCH, AND INTRODUCTION OF THE NURTURING CARE FOR ECD FRAMEWORK, WHICH SETS THE STRUCTURE FOR COUNTRIES TO ADOPT, ADAPT, AND SCALE ECD SERVICES. PATH'S PIONEERING WORK TO INTEGRATE ECD INTO HEALTH SYSTEMS HAS FOCUSED ON BUILDING AN ENABLING LEADERSHIP AND POLICY ENVIRONMENT WHILE SUPPORTING AND BUILDING THE CAPACITY OF EXISTING HEALTH SERVICE SYSTEMS AND PROVIDERS AT BOTH THE FACILITY AND COMMUNITY LEVELS AND STRENGTHENING REFERRAL SYSTEMS. PATH ALSO CONTINUED EFFORTS TO ENSURE THAT ALL INFANTS RECEIVE HUMAN MILK. OUR EFFORTS CENTER AROUND AN INTEGRATED MODEL FOR BREASTFEEDING PROMOTION, INCLUDING THE PROVISION OF SAFE DONOR MILK THROUGH HUMAN MILK BANKS. PATH DEVELOPED STRENGTHENING HUMAN MILK BANKING: A RESOURCE TOOLKIT FOR ESTABLISHING AND OPERATING HUMAN MILK BANK PROGRAMS, THE FIRST-EVER STANDARD TO ENSURE QUALITY AND SAFETY. PATH CONTINUED TO ADVOCATE FOR POLICIES TO GUIDE APPROPRIATE AND ETHICAL USE OF DONOR HUMAN MILK, WORKING WITH GLOBAL TECHNICAL AND POLICY LEADERS TO DRIVE SCALE-UP. PATH WORKED WITH THE KENYA MINISTRY OF HEALTH TO PREPARE FOR THE LAUNCH OF THE FIRST HUMAN MILK BANK IN THE EAST AFRICAN REGION. IN GHANA, THE MAKING EVERY BABY COUNT INITIATIVE STRENGTHENS LEADERSHIP AND CAPACITY AT THE NATIONAL AND LOCAL LEVELS TO MANAGE AND SUSTAIN BEST PRACTICES IN NEWBORN CARE. IN 2018, PATH SUPPORTED GHANA'S CENTRAL GOVERNMENT AND REGIONS TO REDUCE NEONATAL MORTALITY THROUGH SPECIFIC ACTIVITIES THAT IMPROVED AND STANDARDIZED NEWBORN CARE. RECOGNIZING THAT NUTRITION IS AFFECTED BY A VARIETY OF ECONOMIC AND ENVIRONMENTAL FACTORS, PATH'S NUTRITION TEAM CONTINUED TO DRIVE NOVEL APPROACHES TO ADDRESS THE MASSIVE BURDEN OF MALNUTRITION IN COMMUNITIES AROUND THE WORLD. WE ENGAGED STAKEHOLDERS WITH EXPERTISE SPANNING GLOBAL HEALTH, DEVELOPMENT, AND THE ENVIRONMENT, FROM BOTH THE PUBLIC AND PRIVATE SECTORS. IN ADDITION, PATH CONTINUED TO SUPPORT A PROJECT KNOWN AS MAXIMIZING THE QUALITY OF SCALING UP NUTRITION PLUS (MQSUN+). IN THIS PROJECT, PATH LEADS A CONSORTIUM OF FIVE ORGANIZATIONS THAT ARE EXPANDING THE EVIDENCE BASE ON THE CAUSES OF UNDERNUTRITION, ENHANCING THE SKILLS AND CAPACITY OF PARTICIPATING GOVERNMENTS TO SCALE UP NUTRITION-RELATED PROGRAMS AND POLICIES, AND PROVIDING TECHNICAL GUIDANCE ON PROGRAM DESIGN, IMPLEMENTATION, AND M&E. OTHER NUTRITION-RELATED ACTIVITIES IN 2018 INCLUDED COLLABORATION WITH THE NATURE CONSERVANCY, DUKE UNIVERSITY, AND THE INTERNATIONAL FOOD POLICY RESEARCH INSTITUTE TO ADVANCE THE USE OF ALTERNATIVE PROTEINS; THIS WORK WAS FUNDED BY THE ROCKEFELLER FOUNDATION. IN INDIA, WE EXPANDED OUR FORTIFIED RICE SCHOOL FEEDING PROGRAM IN KARNATAKA AND GUJARAT STATES. WE CONTINUED TO DRIVE MULTISECTORAL COLLABORATION IN 2018 BY FURTHERING THE BRIDGE COLLABORATIVE, A TRAILBLAZING, CROSS-DISCIPLINARY EFFORT TO ENGAGE MORE THAN 150 LEADING TECHNICAL EXPERTS FROM THE HEALTH, DEVELOPMENT, AND ENVIRONMENTAL SECTORS TO ADDRESS HUMAN AND PLANETARY HEALTH. WE PUBLISHED SEVERAL PEER-REVIEWED PAPERS AND HELD SEVERAL HIGH-LEVEL MEETINGS ON THE INTERSECTION OF HUMAN AND PLANETARY HEALTH IN CONJUNCTION WITH THE UNITED NATIONS DEVELOPMENT PROGRAM. IN 2018, SEVERAL PATH STAFF MEMBERS PRESENTED AT KEY GLOBAL AND NATIONAL MEETINGS, EMPHASIZING OUR GLOBAL THOUGHT-LEADERSHIP. PATH STAFF ALSO AUTHORED, EDITED, AND CONTRIBUTED TO VARIOUS HIGH-PROFILE PEER-REVIEWED JOURNAL ARTICLES, BOOK CHAPTERS, GLOBAL REPORTS, AND SYSTEMATIC REVIEWS. THESE EFFORTS ADVANCED THINKING ON BROAD, EFFECTIVE SOLUTIONS TO DEEPLY CHALLENGING MATERNAL, FORM 990, PART III, LINE 4A NEWBORN, AND CHILD HEALTH AND NUTRITION PROBLEMS. SEXUAL AND REPRODUCTIVE HEALTH PATH'S WORK IN SEXUAL AND REPRODUCTIVE HEALTH IS GUIDED BY THE KEY PRINCIPLES OF CHOICE, EQUITY, AND DIGNITY FOR ALL WOMEN. BECAUSE WE UNDERSTAND THE COMPLEX SOCIAL, BEHAVIORAL, AND GENDER DIMENSIONS OF WOMEN'S REPRODUCTIVE HEALTH, WE BUILD EVIDENCE AROUND TOOLS AND SERVICES THAT ARE BEST SUITED TO ADDRESS WOMEN'S DIVERSE NEEDS AND CIRCUMSTANCES. WE SPECIALIZE IN REDUCING BARRIERS TO ACCESS. PATH CONTINUES TO CHAMPION THE RIGHT OF WOMEN TO MANAGE THEIR OWN SEXUAL AND REPRODUCTIVE HEALTH NEEDS BY CREATING AND ADVANCING IMPROVED TOOLS AND PRACTICES THAT MAKE WOMEN'S SELF-CARE POSSIBLE. AN INTEGRATED APPROACH TO WOMEN'S HEALTH INCLUDES ATTENTION TO CONTRACEPTION, CERVICAL AND BREAST CANCER, SEXUALLY TRANSMITTED INFECTIONS, THE RIGHT TO DECIDE WHETHER AND WHEN TO BECOME A MOTHER, AND GENDER-BASED VIOLENCE PREVENTION AND CARE SERVICES. WE SPEARHEAD DISCUSSIONS ON THE PRACTICES, BEHAVIORS, AND TOOLS THAT ENABLE WOMEN TO SELF-ASSESS AND SELF-MANAGE THEIR SEXUAL AND REPRODUCTIVE HEALTH NEEDS. AMONG THE RECENT WOMAN-INITIATED PRODUCTS INTRODUCED BY PATH ARE AN ALL-IN-ONE INJECTABLE CONTRACEPTIVE THAT CAN BE SELF-ADMINISTERED AND A VAGINAL SELF-SAMPLING KIT FOR HUMAN PAPILLOMAVIRUS (HPV) TESTING IN CERVICAL CANCER SCREENING PROGRAMS, AS DESCRIBED BELOW. PATH'S RESEARCH AND COORDINATION TO EXPAND ACCESS TO THE INJECTABLE CONTRACEPTIVE SUBCUTANEOUS DMPA (DMPA-SC, OR SAYANA PRESS) CONTINUED IN 2018, PRIMARILY THROUGH THE SELF-INJECTION BEST PRACTICES AND ACCESS COLLABORATIVE PROJECTS. THE SELF-INJECTION PROJECT IN UGANDA LAUNCHED TO GATHER INFORMATION ABOUT HOW THE PRACTICE CAN BE DESIGNED AND IMPLEMENTED AT SCALE. BY THE END OF 2018, AT LEAST 7,000 WOMEN WERE SELF-INJECTING ACROSS FOUR DISTRICTS THROUGH THIS PROGRAM. THE DMPA-SC ACCESS COLLABORATIVE WORKS WITH MINISTRIES OF HEALTH AND PARTNERS ACROSS SECTORS IN TEN COUNTRIES TO FACILITATE DMPA-SC COUNTRY INTRODUCTION AND SCALE-UP PLANNING FOR A RANGE OF CONTRACEPTIVE OPTIONS. IN 2018, THE COLLABORATIVE PROVIDED TECHNICAL ASSISTANCE TO ENSURE IMPLEMENTATION OF EACH COUNTRY'S TOTAL MARKET PLAN. FURTHERMORE, THE COLLABORATIVE FACILITATED LEARNING ACROSS COUNTRIES BY EXCHANGING INFORMATION, RESULTS, AND LESSONS LEARNED; TROUBLESHOOTING CHALLENGES; AND ACCELERATING THE ADOPTION OF BEST PRACTICES. PATH ALSO WORKED WITH PARTNERS WORLDWIDE AND IN SEVERAL COUNTRIES TO IMPROVE THE PREVENTION, DETECTION, AND TREATMENT OF CERVICAL PRECANCER, WHICH IS CAUSED BY INFECTION WITH HPV. WE CONTINUED OUR PARTNERSHIP WITH THE MINISTRIES OF HEALTH IN GUATEMALA, HONDURAS, AND NICARAGUA TO SUPPORT THE SCALE-UP OF HPV TESTING IN THE PUBLIC-SECTOR HEALTH SYSTEM. WE PROVIDED TECHNICAL SUPPORT FOR PROCUREMENT OF TESTS, SUPPORTED ADVOCACY AND DISSEMINATION EVENTS AT THE MINISTRIES OF HEALTH, AND MADE PROGRESS TOWARD TRANSITIONING LEADERSHIP OF THE PROGRAM TO THE MINISTRIES THEMSELVES AS THE PROJECT BEGAN ITS FINAL YEAR. WE DEDICATED ADDITIONAL EFFORTS TO EVALUATING FOLLOW-UP AND TREATMENT STRATEGIES TO ENSURE WOMEN RECEIVE APPROPRIATE CARE DURING EACH STAGE OF A COMPREHENSIVE CERVICAL CANCER PREVENTION PROGRAM. IN MYANMAR, WE ENGAGED WITH THE MINISTRY OF HEALTH AND OTHER STAKEHOLDERS TO DESIGN AN OPERATIONAL PLAN FOR CERVICAL CANCER CONTROL. PATH EXPERTS ALSO PARTICIPATED ACTIVELY IN WHO'S CALL FOR GLOBAL CERVICAL CANCER ELIMINATION BY ATTENDING INTERNATIONAL MEETINGS TO DEFINE ELIMINATION TARGETS AND SHAPE STRATEGIES FOR LOW- AND MIDDLE-INCOME COUNTRIES. TO COMBAT BREAST CANCER, WE WORKED WITH THE NATIONAL CANCER INSTITUTE IN PERU AND OTHER REGIONAL STAKEHOLDERS TO IMPLEMENT A MODEL FOR EARLY DETECTION OF BREAST CANCER THAT IS APPROPRIATE AND FEASIBLE FOR LOW- AND MIDDLE-RESOURCE SETTINGS. WE BUILT THE CAPACITY OF NUMEROUS HEALTH PROFESSIONALS TO IMPLEMENT THIS MODEL AND CONDUCTED ADVOCACY ACTIVITIES AMONG HEALTH OFFICIALS TO ENSURE BREAST CANCER STAYS ON THE AGENDA AND WOMEN RECEIVE SCREENING AND TREATMENT EVEN IN THE ABSENCE OF MAMMOGRAPHY SERVICES. PATH ALSO CONTINUED TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION. THIS IS A GLOBAL PARTNERSHIP OF MORE THAN 400 PUBLIC, PRIVATE, AND NONGOVERNMENTAL ORGANIZATIONS WORKING TO EXPAND ACCESS TO SUPPLIES, SERVICES, AND OPTIONS FOR PREVENTING UNINTENDED PREGNANCY AND SEXUALLY TRANSMITTED INFECTIONS. NONCOMMUNICABLE DISEASES PATH IS AT THE FOREFRONT OF THE FIGHT IN LOW- AND MIDDLE-INCOME COUNTRIES AGAINST NONCOMMUNICABLE DISEASES (NCDS), INCLUDING DIABETES, CARDIOVASCULAR DISEASE, AND WOMEN'S CANCERS. THESE DISEASES ARE RESPONSIBLE FOR TWO-THIRDS OF DEATHS WORLDWIDE, AND ALMOST 75 PERCENT OF THESE DEATHS OCCUR IN LOWER-RESOURCE SETTINGS. IN 2018, PATH CONTINUED TO EXPAND OUR NCD PROGRAM. THROUGH THIS PROGRAM, PATH SERVES AS THE SECRETARIAT OF THE COALITION FOR ACCESS TO NCD MEDICINES & PRODUCTS, WHICH WAS LAUNCHED IN 2017. THIS GLOBAL, MULTISECTORAL COALITION IS DEDICATED TO INCREASING ACCESS TO NCD MEDICINES AND HEALTH PRODUCTS IN LOW- AND MIDDLE-INCOME COUNTRIES. MEMBERS INCLUDE GOVERNMENT AGENCIES, PRIVATE-SECTOR ENTITIES, NONGOVERNMENTAL ORGANIZATIONS, PHILANTHROPIC FOUNDATIONS, AND ACADEMIC INSTITUTIONS. IN ADDITION TO ITS GLOBAL ADVOCACY EFFORTS, THE COALITION BEGAN IMPLEMENTATION ACTIVITIES IN EAST AFRICA, STARTING WITH KENYA AND UGANDA, FOCUSING ON SUPPLY CHAIN STRENGTHENING, LANDSCAPING, AND A COSTING STUDY. IN KENYA, PATH CONTINUED TO IMPLEMENT A FIRST-OF-ITS-KIND PROGRAM THAT INTEGRATES SCREENING AND CARE FOR HYPERTENSION INTO HIV/AIDS SERVICES. THE PROGRAM WAS IN FULL IMPLEMENTATION IN 2018, WITH 51 PARTICIPATING FACILITIES. FURTHERMORE, IN PARTNERSHIP WITH KENYA'S MINISTRY OF HEALTH, PATH LAUNCHED THE NCD NAVIGATOR (PREVIOUSLY CALLED THE GLOBAL ASSESSMENT FRAMEWORK) TO MAP NCD INITIATIVES IN KENYA AND INFORM STRATEGIC PLANNING EFFORTS, IDENTIFY GAPS AND AREAS OF OVERLAP, AND SUPPORT GREATER ALIGNMENT WITH THE NATIONAL STRATEGY. IN SENEGAL, IN COLLABORATION WITH INTRAHEALTH AND THE MINISTRY OF HEALTH AND SOCIAL ACTION, PATH IMPLEMENTED THE BETTER HEARTS BETTER CITIES PROJECT. THE PROJECT'S AMBITIOUS AIM IS TO IMPROVE THE HYPERTENSION CONTROL RATE IN DAKAR. IN VIETNAM, PATH IMPLEMENTED THE COMMUNITIES FOR HEALTHY HEARTS PROJECT TO IMPROVE BLOOD PRESSURE CONTROL AMONG ADULTS BY INCREASING ACCESS TO AND USE OF HIGH-QUALITY HYPERTENSION SERVICES THAT ARE SUSTAINABLE AND SCALABLE. THE PROJECT DIRECTLY BENEFITS 700,000 PEOPLE IN FOUR DISTRICTS IN HO CHI MINH CITY. BY THE END OF 2018, NEARLY 33 PERCENT OF PEOPLE SCREENED WERE FOUND TO HAVE HIGH BLOOD PRESSURE MEASUREMENTS AND WERE REFERRED FOR HYPERTENSION DIAGNOSIS, TREATMENT, AND MANAGEMENT (IF REQUIRED). PATH IS ALSO IMPLEMENTING A PROJECT FOCUSED ON HYPERTENSION SCREENING IN URBAN SLUMS IN MUMBAI, INDIA, IN PARTNERSHIP WITH RESOLVE TO SAVE LIVES. THE PROJECT USES A PRIVATE-SECTOR ENGAGEMENT MODEL TO IMPROVE HYPERTENSION SCREENING, DIAGNOSIS, AND CARE. IN ADDITION, PATH LED AND CONTRIBUTED TO CONVENINGS TO RAISE AWARENESS OF NCDS AND ORCHESTRATE ACTION TO IMPROVE ACCESS TO PREVENTION AND CARE FOR PEOPLE AT RISK FOR OR LIVING WITH THESE DISEASES. HEALTH SYSTEMS INNOVATION AND DELIVERY PATH'S HEALTH SYSTEMS INNOVATION AND DELIVERY PROGRAM IMPROVES THE HEALTH AND WELL-BEING OF PEOPLE IN LOW- AND MIDDLE-INCOME COUNTRIES BY STRENGTHENING HEALTH SYSTEMS AND ENHANCING COUNTRY CAPACITY FOR DATA-DRIVEN DECISION-MAKING. OUR PORTFOLIO SERVES AS AN ORGANIZING MECHANISM FOR PATH PROJECTS, INITIATIVES, AND UNITS THAT STRENGTHEN HEALTH SYSTEMS. THE HEALTH SYSTEMS ANALYTICS UNIT PROMOTES SYSTEMS THINKING IN THE DESIGN, IMPLEMENTATION, SCALE-UP, AND EVALUATION OF HEALTH PROGRAMS AND TECHNOLOGIES. WITHIN AND OUTSIDE OF PATH, THIS UNIT LEADS COMPLEX EVALUATIONS, ENGAGES IN IMPLEMENTATION SCIENCE RESEARCH, FACILITATES HEALTH TECHNOLOGY INTRODUCTION AND SCALE-UP, AND WORKS TO IMPROVE DATA QUALITY AND USE FOR DECISION-MAKING. IN 2018, AS PART OF THE GLOBAL FUND'S PROSPECTIVE COUNTRY EVALUATIONS, THE UNIT CONTINUED EVALUATING THE GLOBAL FUND'S BUSINESS MODEL IN THE DRC, GUATEMALA, AND UGANDA USING A MIXED-METHODS APPROACH. STAFF ENGAGED IN SEVERAL NETWORK ANALYSES TO INFORM THE OPTIMAL STRUCTURE AND FUNCTION OF VARIOUS COALITIONS AND INFORMAL AND FORMAL NETWORKS. PATH STAFF CONTRIBUTED TECHNICAL EXPERTISE TO THE EXPANDED PROGRAM ON IMMUNIZATION'S LEADERSHIP AND MANAGEMENT PROGRAM, LED BY YALE UNIVERSITY AND FUNDED BY GAVI, THE VACCINE ALLIANCE. THE HEALTH SYSTEMS STRENGTHENING IMPACT TEAM CONTINUED TO SERVE AS A HUB FOR STAFF WORKING IN HEALTH SYSTEMS. THE GROUP CONVENED TO PLAN FOR FUTURE WORK IN STRENGTHENING URBAN HEALTH SYSTEMS, IMPROVING COMMUNITY-LEVEL DATA USE, AND DEVELOPING RESOURCES FOR SUCCESSFUL INTRODUCTION AND SCALE-UP OF INTERVENTIONS AND TECHNOLOGIES. THIS TEAM ALSO DEVELOPED PATH'S PRIMARY HEALTH CARE STRATEGY. THE GLOBAL HEALTH SECURITY TEAM CONTINUED TO INNOVATE SYSTEMS FOR THE PREVENTION, DETECTION, AND CONTROL OF INFECTIOUS DISEASE FORM 990, PART III, LINE 4A OUTBREAKS. WITH SUPPORT FROM THE US CENTERS FOR DISEASE CONTROL AND PREVENTION, THE TEAM WORKED WITH NATIONAL LEADERS IN THE DRC, SENEGAL, TANZANIA, AND VIETNAM TO STRENGTHEN THEIR PUBLIC HEALTH SYSTEMS AND BUILD THEIR CAPACITY IN EPIDEMIC PREPAREDNESS AND RESPONSE. THE TEAM ALSO BEGAN WORK AS A MAJOR SUBGRANTEE UNDER ICF INTERNATIONAL FOR SURVEILLANCE ACTIVITIES IN THE USAID-SUPPORTED INFECTIOUS DISEASE DETECTION & SURVEILLANCE PROJECT. THIS PROJECT WORKS TO IMPROVE THE DETECTION OF HIGH-PRIORITY INFECTIOUS DISEASES AND IDENTIFICATION OF ANTIMICROBIAL RESISTANCE THROUGH IMPROVED DIAGNOSTIC AND SURVEILLANCE SYSTEMS. OUR CROSS-ORGANIZATIONAL IMPACT TEAM FOCUSING ON EPIDEMIC PREPAREDNESS AND RESPONSE CONTINUED TO BE AT THE FOREFRONT OF THE EBOLA RESPONSE IN THE DRC, PROVIDING A KEY ROLE IN SURVEILLANCE, DETECTION, AND RESOURCE MOBILIZATION. THE TEAM IS DEVELOPING AND INTRODUCING INNOVATIONS TO STRENGTHEN ELECTRONIC HEALTH INFORMATION SYSTEMS, ADVANCING NOVEL VACCINE PLATFORMS, PREPARING MEDICAL COUNTERMEASURES FOR PANDEMIC INFLUENZA, AND DEFINING PATH'S ROLE IN COMBATING ANTIMICROBIAL RESISTANCE. DIGITAL HEALTH SOLUTIONS PATH USES INFORMATION AND COMMUNICATION TECHNOLOGIES TO IMPROVE HEALTH AND SAVE LIVES. IN 2018, OUR GROWING DIGITAL HEALTH TEAM APPLIED ITS EXPERTISE TO SEVERAL PROJECTS. KEY ACCOMPLISHMENTS INCLUDED LAUNCHING THE WHO-PATH STRATEGIC COLLABORATION ON INNOVATION AND GLOBAL DIGITAL HEALTH. THIS COLLABORATION WILL BRING TOGETHER A CROSS-SECTOR NETWORK OF DIGITAL HEALTH EXPERTS AND INVESTORS TO SUPPORT WHO IN DEVELOPING A GLOBAL DIGITAL HEALTH PORTFOLIO. PATH ALSO LAUNCHED THE CENTER OF DIGITAL AND DATA EXCELLENCE, A BODY DESIGNED TO COORDINATE DIGITAL HEALTH EFFORTS ACROSS PATH. WE CONTINUED WORK UNDER DIGITAL SQUARE, A PATH-LED INITIATIVE. THIS IS A PARTNERSHIP OF THE WORLD'S LEADING DIGITAL HEALTH EXPERTS FROM MORE THAN 40 ORGANIZATIONS AND COUNTRIES WORKING TOGETHER TO STRENGTHEN DIGITAL HEALTH SYSTEMS IN EMERGING ECONOMIES. IN ADDITION, WE COLLABORATED WITH THE JOINT LEARNING NETWORK FOR UNIVERSAL HEALTH COVERAGE TO CONTINUE A PEER LEARNING NETWORK THAT INCLUDES PROFESSIONALS FROM MINISTRIES OF HEALTH AND NATIONAL HEALTH INSURANCE AGENCIES IN TEN COUNTRIES. THESE PROFESSIONALS ARE WORKING TO IMPROVE THEIR HEALTH CARE DATA SYSTEMS, WHICH WILL HELP THEIR COUNTRIES ACHIEVE UNIVERSAL HEALTH COVERAGE. WE CONTINUED IMPLEMENTATION OF THE TANZANIA DATA USE PARTNERSHIP, WHICH SUPPORTS THE GOVERNMENT OF TANZANIA TO IMPROVE COUNTRYWIDE HEALTH INFORMATION SYSTEMS AND IMPLEMENT ITS DIGITAL HEALTH INVESTMENT ROAD MAP. THE BID INITIATIVE, A COLLABORATION BETWEEN PATH AND THE GOVERNMENTS OF TANZANIA AND ZAMBIA, HAS EMPOWERED THESE COUNTRY GOVERNMENTS TO ENHANCE IMMUNIZATION THROUGH IMPROVED DATA COLLECTION, QUALITY, AND USE. THIS PROJECT ENDED IN 2018, AND PROJECT CLOSE-OUT ACTIVITIES INCLUDED THE DOCUMENTATION AND SHARING OF PROJECT LEARNINGS. THE DIGITAL HEALTH TEAM ALSO SUPPORTED THE IMMUNIZATION DATA: EVIDENCE FOR ACTION REVIEW. THIS INITIATIVE REVIEWED AVAILABLE EVIDENCE ON WHAT WORKS TO IMPROVE THE USE OF IMMUNIZATION DATA, SYNTHESIZED THE FINDINGS, AND DISTRIBUTED THE FINDINGS THROUGH AN ADVOCACY AND COMMUNICATIONS CAMPAIGN. COUNTRY PROGRAMS PATH'S COUNTRY PROGRAMS SUPPORT WORK RANGING FROM SMALL-SCALE PILOTS TO LARGE, MULTICOUNTRY EFFORTS. IN 2018, WE OPERATED FULL-SCALE "COUNTRY" OFFICES IN THE DRC, ETHIOPIA, INDIA, KENYA, MYANMAR, SENEGAL, TANZANIA, UGANDA, UKRAINE, VIETNAM, AND ZAMBIA, AS WELL AS SMALLER "PROJECT" OFFICES IN MANY OTHER COUNTRIES. EXAMPLES OF OUR COUNTRY PROGRAM WORK ARE HIGHLIGHTED BELOW, FOCUSING ON THE DRC, KENYA, AND INDIA. IN RESPONSE TO RECURRING EBOLA OUTBREAKS IN THE DRC, PATH HAS FOCUSED ON STRENGTHENING GLOBAL HEALTH SECURITY AND EPIDEMIC PREPAREDNESS IN COLLABORATION WITH THE MINISTRY OF HEALTH (MOH). IN MAY 2018, THE DRC EXPERIENCED ITS SECOND EBOLA OUTBREAK IN LESS THAN 12 MONTHS. IN COLLABORATION WITH THE MOH, PATH DEPLOYED THE FIRST WAVE OF 12 MOH INVESTIGATORS, 10 EPIDEMIOLOGISTS, AND 6 COMMUNICATIONS EXPERTS TO THE CITY OF MBANDAKA TO ASSESS THE OUTBREAK. PATH ALSO ADVISED THE MOH ON IMPLEMENTATION OF A STRATEGY FOR DATA COLLECTION. THIS METHOD USED SATELLITE IMAGERY TO REFINE MAPS SO THE MOH, PATH, AND OTHER KEY PARTNERS COULD BETTER TRACK THE OUTBREAK. UNDER A GLOBAL HEALTH SECURITY EBOLA OUTBREAK RESPONSE GRANT, PATH CONTINUED TO PROVIDE SUPPORT THROUGHOUT THE 2018 OUTBREAK, BUILDING DATA MANAGEMENT AND VISUALIZATION CAPACITY AT THE EMERGENCY OPERATIONS CENTER IN KINSHASA AND COORDINATING WORK ACROSS KEY RESPONDERS, SUCH AS WHO, THE UNITED NATIONS OFFICE FOR THE COORDINATION OF HUMANITARIAN AFFAIRS, AND THE US CENTERS FOR DISEASE CONTROL AND PREVENTION. CONCURRENTLY, PATH CONTINUED TO EXPAND SCREENING FOR HUMAN AFRICAN TRYPANOSOMIASIS (HAT; ALSO CALLED SLEEPING SICKNESS) IN BANDUNDU PROVINCE. IN RECENT YEARS, UP TO 60 TO 80 PERCENT OF ALL CASES WORLDWIDE HAVE BEEN REPORTED FROM THE DRC. RESEARCH HAS SHOWN THAT DISEASE CONTROL HINGES ON ACTIVE POPULATION SCREENING AND VECTOR CONTROL. IN 2018, THIS PROJECT FOCUSED ON EXPANDING ANNUAL SCREENING CAPACITY TO ENSURE THAT AS CASES DECLINE, PEOPLE CONTINUE TO PARTICIPATE IN SCREENINGS. IN PARTNERSHIP WITH PATH AND REGIONAL STAKEHOLDERS, THE MOH ESTABLISHED THE FIRST NATIONAL HAT ELIMINATION DAY ON JANUARY 30, 2018, RE-INVIGORATING LOCAL AUTHORITIES TO ACHIEVE THE GOAL OF ELIMINATION. PATH'S WORK TO IMPROVE HIV/AIDS SERVICE DELIVERY IN THE DRC WAS FIRST CONDUCTED THROUGH THE USAID-FUNDED PROVIC PROJECT AND THEN THROUGH ITS FOLLOW-ON, THE INTEGRATED HIV/AIDS PROJECT IN HAUT-KATANGA AND LUALABA. FROM APRIL 2017 THROUGH JUNE 2018, THE PROJECT TESTED AND INFORMED MORE THAN 286,000 PEOPLE OF THEIR HIV STATUS AND ENROLLED MORE THAN 97 PERCENT OF IDENTIFIED HIV-POSITIVE INDIVIDUALS ON ANTIRETROVIRAL THERAPY. IN KENYA, PATH WORKED TO IMPROVE HIV PREVENTION AND TREATMENT THROUGH A PROJECT CALLED "IMPLEMENTING ASSISTED PARTNER SERVICES SCALE-UP STUDY TO HIV TEST AND TREAT MEN." IN 2018, PROJECT START-UP AND IMPLEMENTATION ACTIVITIES FOCUSED ON ENROLLMENT OF WOMEN AND THEIR MALE SEXUAL CONTACTS IN TWO COUNTIES IN WESTERN KENYA WITH A HIGH HIV BURDEN. WOMEN RECEIVED COUNSELING ON PARTNER NOTIFICATION AND PARTNER ELICITATION CONDUCTED BY THE HIV TESTING SERVICE PROVIDER. ELICITED MALE SEXUAL PARTNERS WERE THEN CONTACTED, NOTIFIED OF THE HIV EXPOSURE, AND OFFERED HIV TESTING. ALL CLIENTS NEWLY IDENTIFIED WERE LINKED TO CARE AND STARTED ON ANTIRETROVIRAL THERAPY. EACH ENROLLED PARTICIPANT WAS FOLLOWED UP PERIODICALLY TO ASSESS HIS OR HER LINKAGE TO CARE, ANTIRETROVIRAL TREATMENT INITIATION, AND VIRAL SUPPRESSION. ALL IDENTIFIED PARTNERS WHO DID NOT HAVE HIV WERE REFERRED FOR PRE-EXPOSURE PROPHYLAXIS TO HELP PREVENT FUTURE INFECTION. PATH ALSO CONTINUED WORK UNDER THE APHIAPLUS PROJECT TO HELP INTEGRATE SERVICE DELIVERY FOR HIV/AIDS AND OTHER HEALTH CONCERNS AND INCREASE THE AVAILABILITY OF SERVICES FOR MARGINALIZED POPULATIONS IN WESTERN KENYA. FROM 2011 THROUGH JUNE 2018, APHIAPLUS AND THE PATH-LED AFYA ZIWANI PROJECT PROVIDED HIV TESTING SERVICES TO MORE THAN 6.7 MILLION INDIVIDUALS IN KENYA, IDENTIFIED MORE THAN 102,600 NEW HIV-POSITIVE INDIVIDUALS, AND SUPPORTED MORE THAN 120,000 PEOPLE LIVING WITH HIV/AIDS ON ANTIRETROVIRAL THERAPY, WITH MORE THAN 80 PERCENT ACHIEVING VIRAL SUPPRESSION. TO STRENGTHEN NEWBORN NUTRITION IN KENYA, PATH IMPLEMENTED A PROJECT CALLED THE "MOTHER-BABY FRIENDLY INITIATIVE-PLUS MODEL FOR HUMAN MILK BANKING." FOR VULNERABLE INFANTS, PATH ADVOCATED FOR A HOLISTIC APPROACH OF BREASTFEEDING PROMOTION AND PROVISION OF SAFE DONOR HUMAN MILK WHEN A MOTHER'S MILK IS NOT AVAILABLE. IN 2018, THE PROJECT WORKED TO ESTABLISH LOCAL OWNERSHIP AND TECHNICAL COMPETENCY IN HUMAN MILK BANKING BY DEVELOPING LEARNING EXCHANGES, CONDUCTING FORMATIVE ASSESSMENTS, AND DEVELOPING A COUNTRY-SPECIFIC STRATEGY FOR HUMAN MILK BANKING. THE PROJECT THEN WORKED TO OPERATIONALIZE THIS STRATEGY TO SET UP A HUMAN MILK BANK FOR LAUNCH IN MARCH 2019. IN INDIA, PATH HAS HELPED TO IMPROVE CHILD NUTRITION THROUGH RICE FORTIFICATION. FOR A DECADE, PATH HAS WORKED CLOSELY WITH INDIAN PARTNERS ON THE FORMULATION OF A FORTIFIED RICE PRODUCT (ULTRA RICE) TO REDUCE THE PREVALENCE OF ANEMIA AND MICRONUTRIENT DEFICIENCIES. IN 2018, PATH WORKED WITH LOCAL PROVIDERS TO BRING FORTIFIED RICE TO SCHOOLCHILDREN ACROSS THE STATE OF GUJARAT. THIS FORTIFIED RICE PROVIDED CHILDREN WITH VITAL MICRONUTRIENTS THAT MAY OTHERWISE BE LACKING IN THEIR DIETS, INCLUDING IRON, FOLIC ACID, VITAMIN A, AND B COMPLEX VITAMINS. IN THE STATE OF UTTAR PRADESH, PATH SUPPORTED LOCAL GOVERNMENT EFFORTS TO ELIMINATE VISCERAL LEISHMANIASIS, ALSO KNOWN AS KALA-AZAR, IN NINE AFFECTED DISTRICTS. KALA-AZAR IS A PARASITIC DISEASE TRANSMITTED BY INFECTED SAND FLIES THAT HAS A HIGH FATALITY RATE WITHOUT PROPER TREATMENT. IN 2018, PATH DEVELOPED TOOLS TO ASSESS THE USE OF PREVENTIVE MEASURES, SUCH AS INDOOR RESIDUAL SPRAYING, AND THE AVAILABILITY FORM 990, PART III, LINE 4A OF DIAGNOSTIC KITS AND DRUGS TO TREAT THE DISEASE. THE PROJECT ALSO STRENGTHENED THE QUALITY OF SURVEILLANCE SYSTEMS BY BUILDING THE CAPACITY OF LOCAL GOVERNMENT. WE SUPPORTED THE GOVERNMENT TO REGULARLY PERFORM DATA QUALITY CHECKS AND CONDUCT DATA VISUALIZATION TO IDENTIFY NEWLY AFFECTED VILLAGES. THIS ENABLED MORE TIMELY DECISION-MAKING AND ACTIONS ON PREVENTION AND TREATMENT. PATH ALSO CONTINUED INNOVATIVE URBAN TB CONTROL EFFORTS IN INDIA. THE PPIA PROJECT, WORKING TO ENHANCE THE ROLE OF PRIVATE HEALTH CARE PROVIDERS IN TB CONTROL, PROVIDED FREE OR SUBSIDIZED SERVICES TO PATIENTS IN MUMBAI WHO WOULD OTHERWISE BE UNABLE TO AFFORD THIS CARE. FROM THE PROJECT'S LAUNCH THROUGH 2018, 202,468 PRESUMPTIVE TB CASES WERE SCREENED AFTER BEING REFERRED FROM THE PRIVATE SECTOR, AND 62,633 PEOPLE (31 PERCENT) WERE DIAGNOSED AND NOTIFIED. A TOTAL OF 49,856 PATIENTS WERE SUPPORTED FOR TREATMENT ADHERENCE MONITORING, AND 2,790 TB PATIENTS WERE LINKED TO PUBLIC-SECTOR SUPPORT. FORM 990, PART VI, SECTION B, LINE 11B THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE DRAFT WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE CHIEF OF ACCOUNTING SIGNED THE FORM. FORM 990, PART VI, SECTION B, LINE 12C PATH HAS POLICIES AND PROCEDURES TO ADDRESS CONFLICTS OF INTEREST. PATH MANAGEMENT AND ALL STAFF AT A DESIGNATED LEVEL OR HIGHER WITHIN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. PATH ALSO HAS A WELL-DEFINED PROCEDURE FOR IDENTIFYING AND REPORTING ACTUAL AND POTENTIAL CONFLICTS OF INTEREST AMONG BOARD MEMBERS. NEW BOARD MEMBERS ARE ASKED TO COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM WITHIN 30 DAYS OF JOINING THE BOARD AND TO COMPLETE A NEW FORM ANNUALLY THEREAFTER. IN ADDITION, MEMBERS ARE REMINDED TO REPORT ANY NEW ISSUES THAT ARISE OUTSIDE OF THE ANNUAL DISCLOSURE PERIOD. THE DISCLOSURE FORMS ARE REVIEWED BY PATH'S GENERAL COUNSEL, AND IF ANY ACTUAL OR POTENTIAL CONFLICTS ARE IDENTIFIED, GENERAL COUNSEL MAKES A RECOMMENDATION TO THE CHAIR OF THE GOVERNANCE COMMITTEE AND THE CHAIR OF THE BOARD FOR A MANAGEMENT PLAN TO PROPERLY MANAGE ANY CONFLICTS. A FORMAL MANAGEMENT PLAN IS THEN AGREED UPON WITH THE BOARD MEMBER, AND THE ENTIRE BOARD OF DIRECTORS IS INFORMED AT THE NEXT REGULARLY SCHEDULED BOARD MEETING. FORM 990, PART VI, SECTION B, LINE 15 THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE ANNUALLY REVIEWS SALARIES AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE PRESIDENT/CHIEF EXECUTIVE OFFICER (CEO) ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT/CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS). THE MOST RECENT MAJOR REVIEW WAS COMPLETED BY THE BOARD COMPENSATION COMMITTEE IN 2017. AT THE REQUEST OF THE BOARD, PATH ENGAGED MERCER (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS. MERCER USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE REVIEWED THE MERCER REPORT AND APPROVED THE USE OF THE REPORT TO ESTABLISH A FRAMEWORK WITHIN WHICH THE PRESIDENT/CEO IS DELEGATED AUTHORITY TO ESTABLISH THE TOTAL COMPENSATION PACKAGES OF THE VICE PRESIDENTS AND EXECUTIVE TEAM MEMBERS. ADDITIONALLY, MERCER REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFITS PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE COMMITTEE'S RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE. FORM 990, PART VI, SECTION C, LINE 19 PATH GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS ARE AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. FORM 990, PART XI, LINE 9: FOR THE YEAR ENDED DECEMBER 31, 2018, THE ORGANIZATION ADOPTED THE FINANCIAL ACCOUNTING STANDARDS BOARD'S ACCOUNTING STANDARDS UPDATE (ASU) NO. 2018-08 - NOT-FOR-PROFIT ENTITIES (TOPIC 958): CLARIFYING THE SCOPE AND THE ACCOUNTING GUIDANCE FOR CONTRIBUTIONS RECEIVED AND CONTRIBUTIONS MADE FOR REVENUE TRANSACTIONS. THE UPDATE ASSISTS ENTITIES IN (1) EVALUATING WHETHER TRANSACTIONS SHOULD BE ACCOUNTED FOR AS CONTRIBUTIONS (NONRECIPROCAL TRANSACTIONS) OR AS EXCHANGE (RECIPROCAL) TRANSACTIONS AND (2) DETERMINING WHETHER A CONTRIBUTION IS CONDITIONAL. THE PRIMARY EFFECT OF ADOPTION OF THIS ASU FOR THE ORGANIZATION IS THAT CERTAIN AWARDS RECEIVED THAT WERE PREVIOUSLY TREATED AS UNCONDITIONAL ARE NOW TREATED AS CONDITIONAL. AS A RESULT, REVENUE FOR THESE AWARDS IS RECOGNIZED WHEN THE CONDITIONS ARE MET DURING THE AWARD TERM, WHEREAS PREVIOUSLY REVENUE HAD BEEN RECOGNIZED WHEN THE AWARDS WERE AWARDED. PATH HAS ELECTED TO ADOPT THE CHANGES FROM THIS ASU RETROSPECTIVELY TO THE 2017 FINANCIAL STATEMENTS. THE NET EFFECT OF THIS CHANGE IS PRESENTED AS AN OTHER CHANGE IN NET ASSETS. -378,755,643. PATH VACCINE SOLUTIONS 2201 WESTLAKE AVENUE SEATTLE WA 98109 830431851 ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN WA 501(C)(3) LINE 12A, I PATH 1 PATH DRUG SOLUTIONS 280 UTAH AVENUE SUITE 250 SAN FRANCISCO CA 94080 943384500 DEVELOPMENT & DISTRIBUTION OF SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES CA 501(C)(3) LINE 12A, I PATH 1 FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND 207 ROUTE DE FERNEY 1218 LE GRAND-S GENEVA SZ EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH SZ 501(C)(3) PATH 1 0 1 1 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 PATH VACCINE SOLUTIONS C 20062779 FMV PATH DRUG SOLUTIONS C 2964636 FMV FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND C 520410 FMV FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND B 3321058 FMV